ES2590038T3 - Oxazine derivative - Google Patents
Oxazine derivative Download PDFInfo
- Publication number
- ES2590038T3 ES2590038T3 ES10836054.6T ES10836054T ES2590038T3 ES 2590038 T3 ES2590038 T3 ES 2590038T3 ES 10836054 T ES10836054 T ES 10836054T ES 2590038 T3 ES2590038 T3 ES 2590038T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- alkylsulfinyl
- acyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
Un compuesto de fórmula (1):**Fórmula** en donde el anillo A es un carbociclo sustituido o un heterociclo sustituido o no sustituido, R1 es alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, acilo sustituido o no sustituido, ciano, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido o carbamoílo sustituido o no sustituido, tiocarbamoilo sustituido o no sustituido, un grupo carbocíclico sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, R2a y R2b son, cada uno independientemente, hidrógeno, alquilo sustituido o no sustituido, acilo sustituido o no sustituido, alcoxicarbonilo sustituido o no sustituido o carbamoílo sustituido o no sustituido, en la que Rza y Rzb son, cada uno independientemente, hidrógeno, halógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alcoxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido, alquiniloxi sustituido o no sustituido, alquiltio sustituido o no sustituido, alqueniltio sustituido o no sustituido, alquiniltio sustituido o no sustituido, acilo sustituido o no sustituido, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, amino sustituido o no sustituido, carbamoílo sustituido o no sustituido, tiocarbamoílo sustituido o no sustituido, un grupo carbocíclico sustituido o no sustituido, carbocicliloxi sustituido o no sustituido, carbocicliltio sustituido o no sustituido, carbociclilalquilo sustituido o no sustituido. carbociclilalcoxi sustituido o no sustituido, carbocicliloxicarbonilo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, heterocicliloxi sustituido o no sustituido, heterocicliltio sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, heterociclilalcoxi no sustituido o sustituido, heterocicliloxicarbonilo sustituido o no sustituido, o Rza y Rzb, junto con el átomo de carbono al que están unidos, pueden formar un carbociclo no aromático sustituido o no sustituido o un heterociclo no aromático sustituido o no sustituido, R3a, R3b, R3c, R4a, R4b y R4c son, cada uno independientemente, hidrógeno, halógeno, hidroxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alcoxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido o alquiniloxi sustituido o no sustituido, alquiltio sustituido o no sustituido, alqueniltio sustituido o no sustituido, alquiniltio sustituido o no sustituido, acilo sustituido o no sustituido, aciloxi sustituido o no sustituido, ciano, nitro, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, amino sustituido o no sustituido, carbamoílo sustituido o no sustituido, tiocarbamoílo sustituido o no sustituido, sulfamoílo sustituido o no sustituido, alquilsulfinilo sustituido o no sustituido, alquenilsulfinilo sustituido o no sustituido, alquinilsulfinilo sustituido o no sustituido, alquilsulfonilo sustituido o no sustituido, alquenilsulfonilo sustituido o no sustituido, alquinilsulfonilo sustituido o no sustituido, un grupo carbocíclico sustituido o no sustituido, carbocicliloxi sustituido o no sustituido, carbocicliltio sustituido o no sustituido, carbociclilalquilo sustituido o no sustituido, carbociclilalcoxi sustituido o no sustituido, carbocicliloxicarbonilo sustituido o no sustituido, carbociclilsulfinilo sustituido o no sustituido, carbociclilsulfonilo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, heterocicliloxi sustituido o no sustituido, heterocicliltio sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, heterociclilalcoxi sustituido o no sustituido, heterocicliloxicarbonilo sustituido o no sustituido, heterociclilsulfinilo sustituido o no sustituido o heterociclilsulfonilo sustituido o no sustituido, sustituido, heterocicliloxicarbonilo sustituido o no sustituido, heterociclilsulfinilo sustituido o no sustituido o heterociclilsulfonilo sustituido o no sustituido, R3a y R3b, junto con el átomo de carbono al que están unidos, pueden formar un carbociclo sustituido o no sustituido o un heterociclo sustituido o no sustituido, R4a y R4b, junto con el átomo de carbono al que están unidos, pueden formar un carbociclo sustituido o no sustituido o un heterociclo sustituido o no sustituido, el anillo Q es un carbociclo sustituido o no sustituido, o un heterociclo sustituido o no sustituido, la línea discontinua a, la línea discontinua b y la línea discontinua c significa cada una de forma independiente la presencia o ausencia de un enlace, cuando una línea discontinua a significa la presencia de un enlace, entonces R3b y R4b están ausentes, cuando la línea discontinua b significa la presencia de un enlace, entonces R3c está ausente cuando la línea discontinua c significa la presencia de un enlace, entonces R4c está ausente, Y1 e Y2 son, cada uno independientemente ,-C(R5)(R6)-, -C(R6)>=, -N(R7)-, -N>=, -S-, -SO-, -SO2- u -O-, Y3 e Y4 son, cada uno independientemente, -C(R5)(R6)-, N(R7)-, -S-, -SO-, -SO2- u -O-, R5 y R6 son, cada uno independientemente, hidrógeno, halógeno, hidroxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alcoxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido, alquiniloxi sustituido o no sustituido, alquiltio sustituido o no sustituido, alqueniltio sustituido o no sustituido, alquiniltio sustituido o no sustituido, acilo sustituido o no sustituido, aciloxi sustituido o no sustituido, ciano, nitro, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo, amino sustituido o no sustituido, carbamoílo sustituido o no sustituido, tiocarbamoílo sustituido o no sustituido, sulfamoílo sustituido o no sustituido, alquilsulfinilo sustituido o no sustituido, alquenilsulfinilo sustituido o no sustituido, alquinilsulfinilo sustituido o no sustituido, alquilsulfonilo sustituido o no sustituido, alquenilsulfonilo sustituido o no sustituido, alquinilsulfonilo sustituido o no sustituido, un grupo carbocíclico sustituido o no sustituido, carbocicliloxi sustituido o no sustituido, carbocicliltiio sustituido o no sustituido, carbociclilalquilo sustituido o no sustituido, carbociclilalcoxi sustituido o no sustituido, carbocicliloxicarbonilo sustituido o no sustituido, carbociclilsulfinilo sustituido o no sustituido, carbociclilsulfonilo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, heterocicliloxi sustituido o no sustituido, heterocicliltio sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, heterociclilalcoxi sustituido o no sustituido, heterocicliloxicarbonilo sustituido o no sustituido, heterociclilsulfinilo sustituido o no sustituido, heterociclilsulfonilo sustituido o no sustituido y R7 es hidrógeno, halógeno, hidroxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alcoxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido, alquiniloxi sustituido o no sustituido, acilo sustituido o no sustituido, aciloxi sustituido o no sustituido, ciano, nitro, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, alquilsulfinilo sustituido o no sustituido, alquenilsulfinilo sustituido o no sustituido, alquinilsulfinilo sustituido o no sustituido, alquilsulfonilo sustituido o no sustituido, alquenilsulfonilo sustituido o no sustituido, alquinilsulfonilo sustituido o no sustituido, carbamoílo sustituido o no sustituido, tiocarbamoílo sustituido o no sustituido, sulfamoílo sustituido o no sustituido, amino sustituido o no sustituido, un grupo carbocíclico sustituido o no sustituido, carbocicliloxi sustituido o no sustituido, carbocicliltio sustituido o no sustituido, carbociclilalquilo sustituido o no sustituido, carbociclilalcoxi sustituido o no sustituido, carbocicliloxicarbonilo sustituido o no sustituido, carbociclilsulfinilo sustituido o no sustituido, carbociclilsulfonilo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, heterocicliloxi sustituido o no sustituido, heterocicliltio sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, heterociclilalcoxi sustituido o no sustituido, heterocicliloxicarbonilo sustituido o no sustituido, heterociclilsulfinilo sustituido o no sustituido o heterociclilsulfonilo sustituido o no sustituido, los sustituyentes de "carbociclo sustituido" y "heterociclo sustituido o no sustituido" en el anillo A, el anillo A' y el anillo B son, si están presentes, uno o más sustituyentes seleccionados de un grupo seleccionado del grupo sustituyente α; en donde el grupo sustituyente α es un grupo que consiste en halógeno, hidroxi, alcoxi, haloalcoxi, hidroxialcoxi, alcoxialcoxi, acilo, aciloxi, carboxi, alcoxicarbonilo, amino, acilamino, alquilamino, imino, hidroxiimino, alcoxiimino, alquiltio, carbamoilo, alquilcarbamoilo, hidroxialquilcarbamoílo, sulfamoílo, alquilsulfamoilo, alquilsulfinilo, alquilsulfonilamino, alquilsulfonilalquilamino, alquilsulfonilimino, alquilsulfinilamino, alquilsulfinilalquilamino, alquilsulfinilimino, ciano, nitro, un grupo carbocíclico y un grupo heterocíclico, cada uno de los cuales carbociclo y heterociclo está opcionalmente sustituido con uno o más sustituyentes seleccionados de halógeno, alquilo, hidroxi y alcoxi: alquilo sustituido con uno o más grupos seleccionados del grupo sustituyente α, hidroxiimino y alcoxiimino, o aA compound of formula (1): ** Formula ** wherein ring A is a substituted carbocycle or a substituted or unsubstituted heterocycle, R1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, cyano, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl or substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted carbocyclic group, a group substituted or unsubstituted heterocyclic, R2a and R2b are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl or substituted or unsubstituted carbamoyl, in which Rza and Rzb are each one independently, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, alkyne substituted or unsubstituted yl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy substituted or unsubstituted carbocyclyl, substituted or unsubstituted carbocyclyl alkyl. substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, unsubstituted heterocyclic or unsubstituted heterocyclyl or Rza and Rzb, together with the carbon atom to which they are attached, can form a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle, R3a, R3b, R3c, R4a, R4b and R4c are, each one independently, hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy or substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio , substituted or unsubstituted alkenylthio, substituted alkylthio unsubstituted or substituted, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted carbamoyl or unsubstituted, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, alkylsulfonyl , a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted carbocyclylsulfinyl or unsubstituted, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclyloxycarbonyloxycarbonyloxy or unsubstituted or substituted or unsubstituted heterocyclylsulfonyl, substituted, unsubstituted or substituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, R3a and R3b, together with the carbon atom to which they are attached, can form a substituted carbocycle or unsubstituted or a substituted or unsubstituted heterocycle, R4a and R4b, together with the carbon atom to which they are attached, can form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, the Q ring is a substituted carbocycle or no substitute uido, or a substituted or unsubstituted heterocycle, the broken line a, the broken line b and the broken line c each independently means the presence or absence of a link, when a broken line a means the presence of a link, then R3b and R4b are absent, when the dashed line b means the presence of a link, then R3c is absent when the dashed line c means the presence of a link, then R4c is absent, Y1 and Y2 are, each independently, -C (R5) (R6) -, -C (R6)> =, -N (R7) -, -N> =, -S-, -SO-, -SO2- or -O-, Y3 and Y4 are, each one independently, -C (R5) (R6) -, N (R7) -, -S-, -SO-, -SO2- or -O-, R5 and R6 are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, alkyl substituted or unsubstituted thio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulphonyl, alkenyl or unsubstituted, substituted or unsubstituted alkylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, carbocyclyloxycarbon substituted or unsubstituted ilo, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclyl, substituted heterocyclyl substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl, substituted or unsubstituted heterocyclylsulfonyl and R7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted alkyloxycarbonyl oo unsubstituted, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulphonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted carbamoyl, thio substituted, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, unsubstituted carbocyclyloxy substituted, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or heterocyclyl alkyl unsubstituted, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl or substituted or unsubstituted heterocyclylsulfonyl, substituents of "substituted carbocycle" and "substituted or unsubstituted heterocycle" in ring A, ring A 'and ring B are, if present, one or more substituents selected from a group selected from the substituent group α; wherein the substituent group α is a group consisting of halogen, hydroxy, alkoxy, haloalkoxy, hydroxyalkoxy, alkoxyalkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, amino, acylamino, alkylamino, imino, hydroxyimino, alkoxyimino, alkylthio, carbamoyl, alkylcarbamoyl, hydroxyalkylcarbamoyl, sulfamoyl, alkylsulfamoyl, alkylsulfinyl, alkylsulphonylamino, alkylsulfonylalkyl amino, alkylsulfonylimino, alkylsulfinylamino, alkylsulfinyl alkylamino, alkylsulfinylimino, cyano, nitro, a carbocyclic group and a heterocyclic groups with one or more of which are substituted for one or more of which one is selected from each one halogen, alkyl, hydroxy and alkoxy: alkyl substituted with one or more groups selected from the substituent group α, hydroxyimino and alkoxyimino, or
Description
5 5
10 10
15 fifteen
20 twenty
25 25
30 30
35 35
40 40
45 Four. Five
Y1 e Y2 son, cada uno independientemente ,-C(R5)(R6)-, -C(R5)=, -N(R7)-, -N=, -S-, -SO-, -SO2-u -O-, Y3 e Y4 son, cada uno independientemente, -C(R5)(R6)-, -C(R5)=, -N(R7)-, -S-, -SO-, -SO2-u -O-, R5 y R6 son, cada uno independientemente, hidrógeno, halógeno, hidroxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alcoxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido alquiniloxi sustituido o no sustituido, alquiltio sustituido o no sustituido, alqueniltio sustituido o no sustituido, alquiniltio sustituido o no sustituido, acilo sustituido o no sustituido, aciloxi sustituido o no sustituido, ciano, nitro, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, amino sustituido o no sustituido, carbamoílo sustituido o no sustituido, tiocarbamoílo sustituido o no sustituido, sulfamoílo sustituido o no sustituido, alquilsulfinilo sustituido o no sustituido, alquenilsulfinilo sustituido o no sustituido, alquinilsulfinilo sustituido o no sustituido, alquilsulfonilo sustituido o no sustituido, alquenilsulfonilo sustituido o no sustituido, alquinilsulfonilo sustituido o no sustituido, un grupo carbocíclico sustituido o no sustituido, carbocicliloxi sustituido o no sustituido, carbocicliltio sustituido o no sustituido, carbocicliloxicarbonilo sustituido o no sustituido, carbociclilsulfinilo sustituido o no sustituido, carbociclilsulfonilo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, heterocicliloxi sustituido o no sustituido, heterocicliltio sustituido o no sustituido, heterocicliloxicarbonilo sustituido o no sustituido, heterociclilsulfinilo sustituido o no sustituido, heterociclilsulfonilo sustituido o no sustituido, y R7 es hidrógeno, halógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alcoxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido, alquiniloxi sustituido o no sustituido, acilo sustituido o no sustituido, aciloxi sustituido o no sustituido, ciano, nitro, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, alquilsulfinilo sustituido o no sustituido, alquenilsulfinilo sustituido o no sustituido, alquinilsulfinilo sustituido Y1 and Y2 are each independently -C (R5) (R6) -, -C (R5) =, -N (R7) -, -N =, -S-, -SO-, -SO2-u - O-, Y3 and Y4 are each independently -C (R5) (R6) -, -C (R5) =, -N (R7) -, -S-, -SO-, -SO2-u -O -, R5 and R6 are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkynyloxy substituted, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or non-substituted sulfamoyl ituido, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, a substituted or unsubstituted carbocyclic group, carbocyclic substituted, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy substituted or unsubstituted heterocyclyloxy substituted, substituted or unsubstituted heterocyclylsulfinyl, substituted or unsubstituted heterocyclylsulfonyl, and R7 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted alkylsulfinyl
- o no sustituido, alquilsulfonilo sustituido o no sustituido, alquenilsulfonilo sustituido o no sustituido, alquinilsulfonilo sustituido o no sustituido, carbamoílo sustituido o no sustituido, tiocarbamoílo sustituido o no sustituido, sulfamoílo sustituido o no sustituido, amino sustituido o no sustituido, un grupo carbocíclico sustituido o no sustituido, carbocicliloxi sustituido o no sustituido, carbocicliloxicarbonilo sustituido o no sustituido, carbociclilsulfinilo sustituido or unsubstituted, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, a substituted carbocyclic group or unsubstituted, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted carbocyclylsulfinyl
- o no sustituido, carbociclilsulfonilo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, heterocicliloxi sustituido o no sustituido, heterocicliloxicarbonilo sustituido o no sustituido, heterociclilsulfinilo sustituido o no sustituido, heterociclilsulfonilo sustituido o no sustituido, con exclusión de los compuestos en donde or unsubstituted, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl, substituted or unsubstituted heterocyclylsulfonyl, excluding the compounds
[Fórmula Química 12] [Chemical Formula 12]
en el que el anillo A' y el anillo B son, cada uno independientemente, un carbociclo sustituido o no sustituido o un heterociclo sustituido o no sustituido, Z es -L1-N(R8)-L2-, L1 y L2 son, cada uno independientemente, un enlace, alquileno sustituido o no sustituido, alquenileno sustituido o no sustituido o alquinileno sustituido o no sustituido; y R8 es hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, acilo sustituido o no sustituido, su sal farmacéuticamente aceptable o un solvato del mismo. Cuando Z es "-L1-N(R8)-L2-", entonces "L1” se une al anillo B y “L2" se une al anillo A’, respectivamente. wherein ring A 'and ring B are each independently a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, Z is -L1-N (R8) -L2-, L1 and L2 are, each one independently, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene; and R8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, its pharmaceutically acceptable salt or a solvate thereof. When Z is "-L1-N (R8) -L2-", then "L1" joins ring B and "L2" joins ring A ', respectively.
(2) El compuesto de acuerdo con cualquiera de los puntos (1), (1-1) y (1-2), en el que el anillo A es [Fórmula Química 13] (2) The compound according to any of items (1), (1-1) and (1-2), in which ring A is [Chemical Formula 13]
9 9
5 5
10 10
15 fifteen
20 twenty
25 25
30 30
35 35
40 40
- (10) (10)
- El compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (9), en el que R2a y R2b son ambos hidrógeno, su sal farmacéuticamente aceptable o un solvato del mismo. The compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1) to (5-6) and (6) to (9), wherein R2a and R2b are both hydrogen, its pharmaceutically acceptable salt or a solvate thereof.
- (11) (eleven)
- Una composición farmacéutica que comprende el compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (10), su sal farmacéuticamente aceptable o un solvato del mismo como un ingrediente activo. A pharmaceutical composition comprising the compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1) to (5-6) and (6) to (10), its pharmaceutically acceptable salt or a solvate thereof as an active ingredient.
- (12) (12)
- Una composición farmacéutica que tiene actividad inhibidora de BACE1, que comprende el compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (10), su sal farmacéuticamente aceptable o un solvato del mismo como un ingrediente activo. A pharmaceutical composition having BACE1 inhibitory activity, which comprises the compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1 ) to (5-6) and (6) to (10), its pharmaceutically acceptable salt or a solvate thereof as an active ingredient.
- (14) (14)
- El compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (10), su sal farmacéuticamente aceptable o un solvato del mismo para uso en un método para inhibir la actividad de BACE1. The compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1) to (5-6) and (6) to (10), its pharmaceutically acceptable salt or a solvate thereof for use in a method to inhibit the activity of BACE1.
- (15) (fifteen)
- Uso de un compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (10), su sal farmacéuticamente aceptable, o solvato del mismo para la fabricación de un medicamento para inhibir la actividad de BACE1. Use of a compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1) to (5-6) and (6 ) to (10), its pharmaceutically acceptable salt, or solvate thereof for the manufacture of a medicament to inhibit the activity of BACE1.
- (17) (17)
- Uso de un compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (10), su sal farmacéuticamente aceptable, o solvato del mismo para la fabricación de un medicamento para tratar o prevenir enfermedades inducidas por la producción, la secreción o la deposición de proteínas β amiloide. Use of a compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1) to (5-6) and (6 ) to (10), its pharmaceutically acceptable salt, or solvate thereof for the manufacture of a medicament for treating or preventing diseases induced by the production, secretion or deposition of amyloid β proteins.
- (18) (18)
- Un compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (10), su sal farmacéuticamente aceptable, o solvato del mismo para uso en el tratamiento o la prevención de enfermedades inducidas por la producción, la secreción o la deposición de proteínas β amiloide. A compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1) to (5-6) and (6) to (10), its pharmaceutically acceptable salt, or solvate thereof for use in the treatment or prevention of diseases induced by the production, secretion or deposition of amyloid β proteins.
- (20) (twenty)
- Uso de un compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (10), su sal o solvato farmacéuticamente aceptable del mismo para fabricar un medicamento para tratar o prevenir la enfermedad de Alzheimer. Use of a compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1) to (5-6) and (6 ) to (10), your pharmaceutically acceptable salt or solvate thereof to make a medicament for treating or preventing Alzheimer's disease.
- (21) (twenty-one)
- Un compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (10), su sal o solvato farmacéuticamente aceptable del mismo para uso en el tratamiento o la prevención de la enfermedad de Alzheimer. A compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1) to (5-6) and (6) to (10), its pharmaceutically acceptable salt or solvate thereof for use in the treatment or prevention of Alzheimer's disease.
- (22) (22)
- Un método, un sistema, un aparato, un kit o similares para la fabricación del compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4) , (5-1) a (5-6) y (6) a (10), su sal farmacéuticamente aceptable o un solvato del mismo. A method, a system, an apparatus, a kit or the like for the manufacture of the compound according to any one of items (1), (1-1), (1-2), (2) to (4), (5-1) to (5-6) and (6) to (10), its pharmaceutically acceptable salt or a solvate thereof.
- (23) (2. 3)
- Un método, un sistema, un aparato, un kit o similares para preparar una composición farmacéutica que comprende el compuesto de acuerdo con uno cualquiera de los puntos (1), (1-1), (1-2), (2) a (4), (5-1) a (5-6) y (6) a (10), su sal farmacéuticamente aceptable o un solvato del mismo. A method, a system, an apparatus, a kit or the like to prepare a pharmaceutical composition comprising the compound according to any one of items (1), (1-1), (1-2), (2) a (4), (5-1) to (5-6) and (6) to (10), its pharmaceutically acceptable salt or a solvate thereof.
- (25) (25)
- Una composición farmacéutica de acuerdo con el punto (11) ó (12) para el tratamiento o la prevención de una enfermedad inducida por la producción, secreción o deposición de proteínas β amiloide. A pharmaceutical composition according to item (11) or (12) for the treatment or prevention of a disease induced by the production, secretion or deposition of amyloid β proteins.
- (26) (26)
- Una composición farmacéutica de acuerdo con el punto (11) ó (12) para tratar o prevenir la enfermedad de Alzheimer. [Efecto de la Invención]. A pharmaceutical composition according to item (11) or (12) to treat or prevent Alzheimer's disease. [Effect of the Invention].
El compuesto de la presente invención es útil como un agente para tratar o prevenir la enfermedad inducida por la producción, secreción o deposición de proteínas amiloide β, tales como la enfermedad de Alzheimer. [Modo de Llevar a cabo la Invención] The compound of the present invention is useful as an agent for treating or preventing disease induced by the production, secretion or deposition of β-amyloid proteins, such as Alzheimer's disease. [How to Carry Out the Invention]
En la memoria descriptiva, el "halógeno" incluye flúor, cloro, bromo y yodo. In the specification, the "halogen" includes fluorine, chlorine, bromine and iodine.
13 5 13 5
10 10
15 fifteen
20 twenty
25 25
30 30
35 35
40 40
En la memoria descriptiva, el "alquilo" incluye alquilo lineal o ramificado de un número de carbonos de 1 a 15, por ejemplo un número de carbonos de 1 a 10, por ejemplo un número de carbonos de 1 a 6 y, por ejemplo, un número de carbonos de 1 a 3. Ejemplos incluyen metilo, etilo, n-propilo, isopropilo, n-butilo, isobutilo, sec.-butilo, terc.-butilo, n-pentilo, isopentilo, neopentilo, hexilo, isohexilo, n-heptilo, isoheptilo, n-octilo, isooctilo, n-nonilo y n-decilo. In the specification, the "alkyl" includes linear or branched alkyl of a number of carbons from 1 to 15, for example a number of carbons from 1 to 10, for example a number of carbons from 1 to 6 and, for example, a number of carbons from 1 to 3. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n -heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl and n-decyl.
Las porciones alquilo en "alcoxi", "haloalquilo", "hidroxialquilo", "haloalcoxi", "hidroxi-alcoxi", "alcoxicarbonilo", "haloalcoxicarbonilo", "alquilamino", "aminoalquilo", "alcoxialcoxi", "alcoxialqueniloxi", "alcoxialquinilo", "alquilcarbonilo", "carbamoílo", "hidroxialquilcarbamoílo", "alcoxiimino", "alquiltio", "alquilsulfonilo", "alquilsulfonilamino", "alquilsulfonilalquilamino", "alquilsulfonilimino", "alquilsulfinilamino", "alquilsulfinilalquilamino", "alquilsulfinilimino", "alquilsulfamoilo", "alquilsulfinilo", "carbociclilalquilo", "carbociclilalcoxi", "carbociclilalcoxicarbonilo", "carbociclilalquilamino", "carbociclilalquilcarbamoílo", "cicloalquilalquilo", "cicloalquilalcoxi", "cicloalquilalquilamino", "cicloalquilalcoxicarbonilo", "cicloalquilalquilcarbamoílo", "arilalquilo", "arilalcoxi", "arilalquilamino", "arilalcoxicarbonilo", "arilalquilcarbamoílo", "heterociclilalquilo", "heterociclilalcoxi", "heterociclilalquilamino", "heterociclilalcoxicarbonilo" y "heterociclilalquilcarbamoílo" son los mismos que el "alquilo" anterior. The alkyl portions in "alkoxy", "haloalkyl", "hydroxyalkyl", "haloalkoxy", "hydroxy-alkoxy", "alkoxycarbonyl", "haloalkoxycarbonyl", "alkylamino", "aminoalkyl", "alkoxyalkoxy", "alkoxyalkenyloxy", "alkoxyalkynyl", "alkylcarbonyl", "carbamoyl", "hydroxyalkylcarbamoyl", "alkoxyimino", "alkylthio", "alkylsulfonyl", "alkylsulfonylamino", "alkylsulfonylalkylamino", "alkylsulfonylimino", "alkylsulfinylaminolamino" "," alkylsulfamoyl "," alkylsulfinyl "," carbocyclylalkyl "," carbocyclylalkoxy "," carbocyclylalkoxycarbonyl "," carbocyclylalkylamino "," carbocyclylalkylcarbamoyl "," cycloalkylalkyl "," cycloalkylalkyl "alkyloalkyl" cycloalkylalkyl " "arylalkyl", "arylalkoxy", "arylalkylamino", "arylalkoxycarbonyl", "arylalkylcarbamoyl", "heterocyclylalkyl", "heterocyclylalkoxy", "heterocyclylalkylamino", "heterocyclylalkoxycarbonyl" and "heterocyclic "alkylcarbamoyl" are the same as the "alkyl" above.
"Alquilo sustituido o no sustituido" puede estar sustituido con uno o más sustituyentes seleccionados de un grupo sustituyente α. "Substituted or unsubstituted alkyl" may be substituted with one or more substituents selected from an α substituent group.
Tal como se utiliza en esta memoria, el grupo sustituyente α es un grupo que consiste en halógeno, hidroxi, alcoxi, haloalcoxi, hidroxialcoxi, alcoxialcoxi, acilo, aciloxi, carboxi, alcoxicarbonilo, amino, acilamino, alquilamino, imino, hidroxiimino, alcoxiimino, alquiltio, carbamoilo, alquilcarbamoilo, hidroxialquilcarbamoílo, sulfamoilo, alquilsulfamoilo, alquilsulfinilo, alquilsulfonilamino, alquilsulfonilalquilamino, alquilsulfonilimino, alquilsulfinilamino, alquilsulfinilalquilamino, alquilsulfinilimino, ciano, nitro, un grupo carbocíclico y un grupo heterocíclico, cada uno de los cuales carbociclo y heterociclo está opcionalmente sustituido con uno o más sustituyentes seleccionados de halógeno, alquilo, hidroxi y alcoxi. As used herein, the substituent group α is a group consisting of halogen, hydroxy, alkoxy, haloalkoxy, hydroxyalkoxy, alkoxyalkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, amino, acylamino, alkylamino, imino, hydroxyimino, alkoxyimino, alkylthio, carbamoyl, alkylcarbamoyl, hydroxyalkylcarbamoyl, sulfamoyl, alkylsulfamoyl, alkylsulfinyl, alkylsulfonylamino, alkylsulfonylalkyl amino, alkylsulfonylimino, alkylsulfinylamino, alkylsulfinylalkyl alkylamino, alkylsulfinylimino, cyano, heterocyclic group, a heterocyclic group of which is a heterocyclic group, a heterocyclic group of which is a heterocyclic group, a heterocyclic group of which is a heterocyclic group, a heterocyclic group of which is a heterocyclic group, a heterocyclic group with a heterocyclic group one or more substituents selected from halogen, alkyl, hydroxy and alkoxy.
Ejemplos de los sustituyentes "alcoxi sustituido o no sustituido", "alcoxicarbonilo sustituido o no sustituido", "alquiltio sustituido o no sustituido", "alquilsulfonilo sustituido o no sustituido" y "alquilsulfinilo sustituido o no sustituido" son uno o más seleccionados del sustituyente grupo α mencionado anteriormente. Examples of the substituents "substituted or unsubstituted alkoxy", "substituted or unsubstituted alkoxycarbonyl", "substituted or unsubstituted alkylthio", "substituted or unsubstituted alkylsulfonyl" and "substituted or unsubstituted alkylsulfinyl" are one or more selected from the substituent α group mentioned above.
Ejemplos de "haloalquilo" son trifluorometilo, fluorometilo y triclorometilo. Examples of "haloalkyl" are trifluoromethyl, fluoromethyl and trichloromethyl.
Ejemplos de "haloalcoxi" son trifluorometoxi, fluorometoxi, triclorometoxi. Examples of "haloalkoxy" are trifluoromethoxy, fluoromethoxy, trichloromethoxy.
El término "alquilideno" incluye un grupo divalente del "alquilo" anterior y ejemplos son metilideno, etilideno, propilideno, isopropilideno, butilideno, pentilideno y hexilideno. The term "alkylidene" includes a divalent group of the above "alkyl" and examples are methylidene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene and hexylidene.
El término "alquenilo" incluye alquenilo lineal o ramificado de un número de carbono de 2 a 15, por ejemplo un número de carbonos de 2 a 10, por ejemplo un número de carbonos de 2 a 6 y, por ejemplo, un número de carbonos de 2 a 4, que tiene uno o más dobles enlaces en cualquier posición disponible. Ejemplos incluyen vinilo, alilo, propenilo, isopropenilo, butenilo, isobutenilo, prenilo, butadienilo, pentenilo, isopentenilo, pentadienilo, hexenilo, isohexenilo, hexadienilo, heptenilo, octenilo, nonenilo, decenilo, undecenilo, dodecenilo, tridecenilo, tetradecenilo y pentadecenilo. The term "alkenyl" includes linear or branched alkenyl of a carbon number from 2 to 15, for example a number of carbons from 2 to 10, for example a number of carbons from 2 to 6 and, for example, a number of carbons 2 to 4, which has one or more double bonds in any available position. Examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl and tetradecentayl.
Las porciones alquenilo en "alqueniloxi", "alqueniloxicarbonilo", "carbonilo", "alcoxialquenilloxi", "alquenilsulfonilo" "alquenilamino", "alqueniltio" y "alquenilsulfinilo" son las mismas que el "alquenilo" anterior. The alkenyl portions in "alkenyloxy", "alkenyloxycarbonyl", "carbonyl", "alkoxyalkenyloxy", "alkenylsulfonyl" "alkenylamino", "alkenylthio" and "alkenyl sulfinyl" are the same as the "alkenyl" above.
El término "alquinilo" incluye un alquinilo lineal o ramificado de un número de carbonos de 2 a 10, preferiblemente un número de carbonos de 2 a 8, más preferiblemente un número de carbonos de 3 a 6 que tiene uno o más triples enlaces en las posiciones opcionales. Ejemplos incluyen etinilo, propinilo, butinilo, pentinilo, hexinilo, heptinilo, octinilo, noninilo y decinilo. Estos pueden tener además un doble enlace en cualquier posición disponible. The term "alkynyl" includes a linear or branched alkynyl of a carbon number of 2 to 10, preferably a carbon number of 2 to 8, more preferably a carbon number of 3 to 6 having one or more triple bonds in the optional positions. Examples include ethynyl, propynyl, butynyl, pentinyl, hexinyl, heptinyl, octinyl, noninyl and decinyl. These can also have a double link in any available position.
Porciones alquinilo en "alcoxialquinilo", "alquiniloxi", "alquiniloxicarbonilo", "alquinilcarbonilo", "alcoxialquiniloxi", "alquiniltio", "alquinilsulfinilo", "alquinilsulfonilo" y "alquinilamino" son las mismas que el "alquinilo" anterior. Alkynyl portions in "alkoxyalkynyl", "alkynyloxy", "alkynyloxycarbonyl", "alkynylcarbonyl", "alkoxyalkyloxy", "alkynylthio", "alkylsulfinyl", "alkylsulfonyl" and "alkylamino" are the same as the "alkynyl" above.
14 5 14 5
10 10
15 fifteen
20 twenty
25 25
30 30
35 35
40 40
Ejemplos del sustituyente de "alqueniloxicarbonilo sustituido o no sustituido", "alquenilsulfinilo sustituido o no sustituido", "alquenilo sustituido o no sustituido", "alqueniloxi sustituido o no sustituido", "alqueniltio sustituido o no sustituido", "alquenilsulfonilo sustituido o no sustituido", "alquinilo sustituido o no sustituido", "alquiniloxi sustituido o no sustituido", "alquiniltio sustituido o no sustituido", "alquiniloxicarbonilo sustituido o no sustituido", "alquinilsulfinilo sustituido o no sustituido" y "alquinilsulfonilo sustituido o no sustituido" son uno o más sustituyentes seleccionados del sustituyente grupo α mencionado anteriormente. Examples of the substituent of "substituted or unsubstituted alkenyloxycarbonyl", "substituted or unsubstituted alkenylsulfinyl", "substituted or unsubstituted alkenyl", "substituted or unsubstituted alkenyloxy", "substituted or unsubstituted alkenylthio", "substituted or unsubstituted alkenyl sulfonyl" "," substituted or unsubstituted alkynyl "," substituted or unsubstituted alkynyloxy "," substituted or unsubstituted alkynylthio "," substituted or unsubstituted alkynyloxycarbonyl "," substituted or unsubstituted alkynylsulfinyl "and" substituted or unsubstituted alkynylsulfonyl "are" one or more substituents selected from the group α substituent mentioned above.
Ejemplos del sustituyente en "amino sustituido o no sustituido", "carbamoílo sustituido o no sustituido", "tiocarbamoílo sustituido o no sustituido" y "sulfamoílo sustituido o no sustituido" son uno o dos sustituyentes seleccionados de entre alquilo, acilo, hidroxi, alcoxi, alcoxicarbonilo, grupo carbocíclico y grupo heterocíclico. Examples of the substituent in "substituted or unsubstituted amino", "substituted or unsubstituted carbamoyl", "substituted or unsubstituted thiocarbamoyl" and "substituted or unsubstituted sulfamoyl" are one or two substituents selected from alkyl, acyl, hydroxy, alkoxy , alkoxycarbonyl, carbocyclic group and heterocyclic group.
El término "acilo" incluye formilo, alquilcarbonilo de un número de carbonos de 1 a 10, alquenilcarbonilo de un número de carbonos de 2 a 10, alquinilcarbonilo de un número de carbonos de 2 a 10, carbociclilcarbonilo y heterociclilcarbonilo. Ejemplos son formilo, acetilo, propionilo, butirilo, isobutirilo, valerilo, pivaloilo, hexanoilo, acriloilo, propiolilo, metacriloilo, crotonoilo, benzoilo, ciclohexanocarbonilo, piridincarbonilo, furancarbonilo, tiofencarbonilo, benzotiazolcarbonilo, pirazincarbonilo, piperidincarbonilo y tiomorfolino. The term "acyl" includes formyl, alkylcarbonyl of a number of carbons from 1 to 10, alkenylcarbonyl of a number of carbons from 2 to 10, alkynylcarbonyl of a number of carbons from 2 to 10, carbocyclylcarbonyl and heterocyclylcarbonyl. Examples are formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propiolilo, methacryloyl, crotonoyl, benzoyl, cyclohexanecarbonyl, pyridinecarbonyl, furancarbonyl, thiophenecarbonyl, benzotiazolcarbonilo, pyrazinecarbonyl, piperidinecarbonyl, and thiomorpholino.
Las porciones de acilo en "aciloxi" y "acilamino" son las mismas que el "acilo" anterior. The acyl portions in "acyloxy" and "acylamino" are the same as the "acyl" above.
Ejemplos de los sustituyentes de "acilo sustituido o no sustituido" y "aciloxi sustituido o no sustituido" son uno o más sustituyentes seleccionados del grupo sustituyente α. Las partes del anillo de carbociclilcarbonilo y heterociclilcarbonilo pueden estar sustituidas con uno o más sustituyentes seleccionados de alquilo, grupo sustituyente α y alquilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α. Examples of the "substituted or unsubstituted acyl" and "substituted or unsubstituted acyloxy" substituents are one or more substituents selected from the α substituent group. The parts of the carbocyclylcarbonyl and heterocyclylcarbonyl ring may be substituted with one or more substituents selected from alkyl, substituent group α and alkyl substituted with one or more substituents selected from substituent group α.
La expresión "grupo carbocíclico" incluye cicloalquilo, cicloalquenilo, arilo y carbociclilo condensado no aromático. The term "carbocyclic group" includes cycloalkyl, cycloalkenyl, aryl and non-aromatic condensed carbocyclyl.
El término "cicloalquilo" incluye un grupo carbocíclico de un número de carbonos de 3 a 10, por ejemplo un número de carbonos de 3 a 8 y, por ejemplo, un número de carbonos de 4 a 8. Ejemplos son ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, cicloheptilo, ciclooctilo, ciclononilo y ciclodecilo. The term "cycloalkyl" includes a carbocyclic group of a number of carbons from 3 to 10, for example a number of carbons from 3 to 8 and, for example, a number of carbons from 4 to 8. Examples are cyclopropyl, cyclobutyl, cyclopentyl , cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl.
Las porciones cicloalquilo en "cicloalquilalquilo", "cicloalquiloxi", "cicloalquilalcoxi", "cicloalquiltio", "cicloalquilamino", "cicloalquilalquilamino", "cicloalquilsulfamoilo", "cicloalquilsulfonilo", "cicloalquilcarbamoílo", "cicloalquilalquilcarbamoílo", "cicloalquilalcoxicarbonilo" y "cicloalquiloxicarbonilo" son las mismas que el "cicloalquilo" anterior. The cycloalkyl portions in "cycloalkylalkyl", "cycloalkyloxy", "cycloalkylalkoxy", "cycloalkylthio", "cycloalkylamino", "cycloalkylalkylamino" "cicloalquilsulfamoilo", "cycloalkylsulfonyl", "cycloalkylcarbamoyl", "cicloalquilalquilcarbamoílo" "cycloalkylalkoxycarbonyl" and "cycloalkyloxycarbonyl "are the same as the" cycloalkyl "above.
El término "cicloalquenilo" incluye un grupo que tiene uno o más dobles enlaces en las posiciones opcionalmente en el anillo de "cicloalquilo" anterior. Ejemplos son ciclopropenilo, ciclobutenilo, ciclopentenilo, ciclohexenilo, cicloheptenilo, ciclooctenilo y ciclohexadienilo. The term "cycloalkenyl" includes a group having one or more double bonds at the positions optionally in the "cycloalkyl" ring above. Examples are cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and cyclohexadienyl.
El término "arilo" incluye fenilo, naftilo, antrilo y fenantrilo. Un ejemplo específico es fenilo. The term "aryl" includes phenyl, naphthyl, antryl and phenanthryl. A specific example is phenyl.
La expresión "grupo carbocíclico condensado no aromático" incluye grupos no aromáticos en los que dos o más grupos cíclicos seleccionados de los anteriores "cicloalquilo", "cicloalquenilo" y "arilo" están condensados. Ejemplos son indanilo, indenilo, tetrahidronaftilo y fluorenilo. The term "non-aromatic condensed carbocyclic group" includes non-aromatic groups in which two or more cyclic groups selected from the above "cycloalkyl", "cycloalkenyl" and "aryl" are condensed. Examples are indanyl, indenyl, tetrahydronaphthyl and fluorenyl.
Las porciones carbociclo en "carbociclo no aromático" son las mismas que "cicloalquilo", "cicloalquenilo" y "grupo carbocíclico no aromático condensado". Ejemplos son ciclopropano, ciclobutano, ciclopentano, ciclohexano, cicloheptano, ciclooctano, ciclononano, ciclodecano, ciclopropeno, ciclobuteno, ciclopenteno, ciclohexeno, ciclohepteno y cicloocteno. The carbocycle portions in "non-aromatic carbocycle" are the same as "cycloalkyl", "cycloalkenyl" and "condensed non-aromatic carbocyclic group". Examples are cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene and cyclooctene.
Las porciones carbociclo en "carbociclo", "carbocicliloxi", "carbociclilalquilo", "carbociclilalcoxi", "carbociclilalcoxicarbonilo", "carbocicliltio", "carbociclilamino", "carbociclilalquilamino", "carbociclilcarbonilo", "carbociclilsulfamoílo", "carbociclilsulfonilo", "carbociclilcarbamoílo", "carbociclilalquilcarbamoílo", "carbocicliloxicarbonilo", "carbociclilsulfinilo" y "carbociclilsulfonilo" son las mismas que las del "grupo carbocíclico" anterior. The carbocycle portions in "carbocycle", "carbocyclyloxy", "carbocyclylalkyl", "carbocyclylalkoxy", "carbocyclylalkoxycarbonyl", "carbocyclylthio", "carbocyclylamino", "carbocyclyl-alkylamino", "carbocyclylcarbonyloxycarbonylalkylcarbonylalkylcarbonylalkylcarbonylalkylcarbonylalkylcarbonylalkylcarbonylalkyl" "," carbocyclyl alkylcarbamoyl "," carbocyclyloxycarbonyl "," carbocyclylsulfinyl "and" carbocyclylsulfonyl "are the same as those of the" carbocyclic group "above.
15 fifteen
en el que el anillo A' y el anillo B son, cada uno independientemente, carbociclo sustituido o heterociclo sustituido o no sustituido, L1, L2 y L3 son, cada uno independientemente, un enlace, alquileno sustituido o no sustituido, alquenileno sustituido wherein the A 'ring and the B ring are each independently substituted or unsubstituted carbocycle or L1, L2 and L3 are each independently a bond, substituted or unsubstituted alkylene, substituted alkenylene
5 o no sustituido o alquinileno sustituido o no sustituido, =W1 es =O, =S o =NR9, W2es O, S o N(R5), R8 es hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido o acilo sustituido o no sustituido, R9 es hidrógeno, hidroxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o 5 or unsubstituted or substituted or unsubstituted alkynylene, = W1 is = O, = S or = NR9, W2 is O, S or N (R5), R8 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, alkynyl substituted or unsubstituted or substituted or unsubstituted acyl, R9 is hydrogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted alkynyl or
10 no sustituido o acilo sustituido o no sustituido, cuando el anillo A es (i), entonces el átomo de carbono constituyente de L1 y el átomo de carbono constituyente de L2, o el átomo de carbono constituyente de L1 y el átomo de nitrógeno de W2 pueden estar conectados con alquileno sustituido o no sustituido para formar un anillo, cuando el anillo A es (ii), entonces el átomo de carbono constituyente de L1 y el átomo de carbono constituyente de 10 unsubstituted or substituted or unsubstituted acyl, when ring A is (i), then the constituent carbon atom of L1 and the constituent carbon atom of L2, or the constituent carbon atom of L1 and the nitrogen atom of W2 may be connected with substituted or unsubstituted alkylene to form a ring, when ring A is (ii), then the constituent carbon atom of L1 and the constituent carbon atom of
15 L2, o el átomo de nitrógeno de W2 y el átomo de carbono constituyente de L2 pueden estar conectados con alquileno sustituido o no sustituido para formar un anillo, cuando el anillo A es (iii), entonces dos átomos de nitrógeno de W2 pueden estar conectados con alquileno sustituido 15 L2, or the nitrogen atom of W2 and the carbon atom constituting L2 can be connected with substituted or unsubstituted alkylene to form a ring, when the ring A is (iii), then two nitrogen atoms of W2 can be connected with substituted alkylene
o no sustituido para formar un anillo, cuando el anillo A es (vi), entonces el átomo de carbono constituyente de L1 y el átomo de carbono constituyente de or unsubstituted to form a ring, when ring A is (vi), then the carbon atom constituting L1 and the carbon atom constituting
20 L2 pueden estar conectados por alquileno sustituido o no sustituido para formar un anillo, p es 1 o 2, y cuando están presentes múltiples L3, múltiples W2 o múltiples R9, cada uno de ellos puede ser independientemente diferente. Ejemplos específicos son los siguientes: 20 L2 may be connected by substituted or unsubstituted alkylene to form a ring, p is 1 or 2, and when multiple L3, multiple W2 or multiple R9 are present, each of them can be independently different. Specific examples are as follows:
25 [Fórmula Química 23] 25 [Chemical Formula 23]
17 17
[Fórmula Química 24] [Chemical Formula 24]
18 18
en la que L es, cada uno independientemente, un enlace, alquileno sustituido o no sustituido, alquenileno sustituido o no sustituido o alquinileno sustituido o no sustituido, el anillo T es un carbociclo opcionalmente sustituido con un o unos grupos seleccionados del grupo sustituyente α, o un heterociclo opcionalmente sustituido con un o unos grupos seleccionados del grupo α, y esos y otros símbolos son los mismos que se han definido anteriormente. wherein L is each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, the T-ring is a carbocycle optionally substituted with one or a few groups selected from the substituent group α, or a heterocycle optionally substituted with one or a few groups selected from the α group, and those and other symbols are the same as defined above.
Ejemplos más específicos son los siguientes: More specific examples are the following:
[Fórmula Química 25] [Chemical Formula 25]
19 19
en la que cada uno de los símbolos es como se ha definido anteriormente. [Fórmula Química 26] in which each of the symbols is as defined above. [Chemical Formula 26]
20 twenty
en la que cada uno de los símbolos es como se ha definido anteriormente. in which each of the symbols is as defined above.
Otros ejemplos del sustituyente de "carbociclo sustituido", "carbociclo sustituido o no sustituido", "heterociclo Other examples of the substituent of "substituted carbocycle", "substituted or unsubstituted carbocycle", "heterocycle
5 sustituido o no sustituido", "benceno sustituido o no sustituido", "piridina sustituida o no sustituida", "pirimidina sustituida o no sustituida" y "pirazina sustituida o no sustituida" en el anillo A, el anillo A' y el anillo B incluyen: un grupo seleccionado del grupo sustituyente α tal como halógeno, hidroxi, alcoxi, acilo, aciloxi, carboxi, alcoxicarbonilo, carbamoilo, amino, ciano, alquilamino y/o alquiltio; alquilo sustituido con uno o más grupos seleccionados del grupo sustituyente α, hidroxiimino y alcoxiimino, en el que 5 substituted or unsubstituted "," substituted or unsubstituted benzene "," substituted or unsubstituted pyridine "," substituted or unsubstituted pyrimidine "and" substituted or unsubstituted pyrazine "in ring A, ring A 'and ring B include: a group selected from the substituent group α such as halogen, hydroxy, alkoxy, acyl, acyloxy, carboxy, alkoxycarbonyl, carbamoyl, amino, cyano, alkylamino and / or alkylthio; alkyl substituted with one or more groups selected from the substituent group α , hydroxyimino and alkoxyimino, in which
10 el sustituyente es, por ejemplo, halógeno, hidroxi, alcoxi y/o alcoxicarbonilo, o alquilo no sustituido; aminoalquilo sustituido con uno o más grupos seleccionados del grupo sustituyente α; en el que el sustituyente es, por ejemplo, acilo, alquilo y/o alcoxi; alquenilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, en el que el sustituyente es, por ejemplo, alcoxicarbonilo, halógeno y/o halogenoalcoxicarbonilo, o alquenilo no sustituido; The substituent is, for example, halogen, hydroxy, alkoxy and / or alkoxycarbonyl, or unsubstituted alkyl; aminoalkyl substituted with one or more groups selected from the α substituent group; wherein the substituent is, for example, acyl, alkyl and / or alkoxy; alkenyl substituted with one or more substituents selected from the α substituent group, wherein the substituent is, for example, alkoxycarbonyl, halogen and / or halogenoalkoxycarbonyl, or unsubstituted alkenyl;
15 alquinilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, en el que el sustituyente es, por ejemplo, alcoxicarbonilo o alquinilo no sustituido; alcoxi sustituido con uno o más sustituyentes seleccionados del Alkynyl substituted with one or more substituents selected from the substituent group α, in which the substituent is, for example, alkoxycarbonyl or unsubstituted alkynyl; alkoxy substituted with one or more substituents selected from the
21 5 21 5
10 10
15 fifteen
20 twenty
25 25
30 30
35 35
40 40
45 Four. Five
50 fifty
55 55
60 60
grupo sustituyente α, en el que el sustituyente es, por ejemplo, halógeno, carbamoilo, alquilcarbamoilo y/o hidroxialquilcarbamoílo; alcoxialcoxi sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α; alqueniloxi sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, en el que el sustituyente es, por ejemplo, halógeno, hidroxi, amino y/o alquilamino, o alqueniloxi no sustituido; alcoxialquenilloxi sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α; alquiniloxi sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, en el que el sustituyente es, por ejemplo, halógeno y/o hidroxi o alquiniloxi no sustituido; alcoxialquiniloxi sustituido con uno o más grupos seleccionados del grupo sustituyente α; alquiltio sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, o alquiltio sustituido; alqueniltio sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, o alqueniltio no sustituido; alquiniltio sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, o alquiniltio no sustituido; alquilamino sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α; alquenilamino sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α; alquinilamino sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α; aminooxi sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α y alquilideno, o aminooxi no sustituido; acilo sustituido con uno o más sustituyentes seleccionados entre el grupo sustituyente α; alquilsulfonilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, o alquilsulfonilo sustituido; alquilsulfinilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, o alquilsulfinilo no sustituido; alquilsulfamoilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α; un grupo carbocíclico tal como cicloalquilo y arilo, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo; un grupo heterocíclico sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo; carbociclilalquilo tal como cicloalquilalquilo y arilalquilo, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbociclilalquilo no sustituido; heterociclilalquilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o heterociclilalquilo sustituido; carbocicliloxi como cicloalquiloxi y ariloxi, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbocicliloxi no sustituido; heterocicliloxi sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o heterocicliloxi no sustituido; carbociclilalcoxi tal como cicloalquilalcoxi y arilalcoxi, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbociclilalcoxi no sustituido; heterociclilalcoxi sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o heterociclilalcoxi no sustituido; carbociclilalcoxicarbonilo tal como cicloalquilalcoxicarbonilo y arilalcoxicarbonilo, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbociclilalcoxicarbonilo no sustituido tal como cicloalquilalcoxicarbonilo y arilalcoxicarbonilo; heterociclilalcoxicarbonilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o heterociclilalcoxicarbonilo no sustituido; carbocicliltio tal como cicloalquiltio y ariltio, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbocicliltio no sustituido tal como cicloalquiltio y ariltio; heterocicliltio sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o heterocicliltio no sustituido; carbociclilamino tal como cicloalquilamino y arilamino, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbociclilamino no sustituido tal como cicloalquilamino y arilamino; heterociclilamino sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o heterociclilamino no sustituido; carbociclilalquilamino tal como cicloalquilalquilamino y arilalquilamino, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo o carbociclilalquilamino no sustituido tal como cicloalquilalquilamino y arilalquilamino; heterociclilalquilamino sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o heterociclilalquilamino no sustituido; carbociclilsulfamoílo tal como cicloalquilsulfamoílo y arilsulfamoílo, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbociclilsulfamoílo no sustituido; heterociclilsulfamoílo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o heterociclilsulfamoílo no sustituido; α substituent group, in which the substituent is, for example, halogen, carbamoyl, alkylcarbamoyl and / or hydroxyalkylcarbamoyl; alkoxyalkoxy substituted with one or more substituents selected from the α substituent group; alkenyloxy substituted with one or more substituents selected from the α substituent group, wherein the substituent is, for example, halogen, hydroxy, amino and / or alkylamino, or unsubstituted alkenyloxy; alkoxyalkenyloxy substituted with one or more substituents selected from the α substituent group; alkynyloxy substituted with one or more substituents selected from the substituent group α, wherein the substituent is, for example, halogen and / or hydroxy or unsubstituted alkynyloxy; alkoxyalkyloxy substituted with one or more groups selected from the α substituent group; alkylthio substituted with one or more substituents selected from the substituent group α, or substituted alkylthio; alkenylthio substituted with one or more substituents selected from the substituent group α, or unsubstituted alkenylthio; alkynylthio substituted with one or more substituents selected from the substituent group α, or unsubstituted alkynylthio; alkylamino substituted with one or more substituents selected from the substituent group α; alkenylamino substituted with one or more substituents selected from the α substituent group; alkylamino substituted with one or more substituents selected from the α substituent group; aminooxy substituted with one or more substituents selected from the substituent group α and alkylidene, or unsubstituted aminooxy; acyl substituted with one or more substituents selected from the substituent group α; alkylsulfonyl substituted with one or more substituents selected from the substituent group α, or substituted alkylsulfonyl; alkylsulfinyl substituted with one or more substituents selected from the substituent group α, or unsubstituted alkylsulfinyl; alkylsulfamoyl substituted with one or more substituents selected from the α substituent group; a carbocyclic group such as cycloalkyl and aryl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl; a heterocyclic group substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl; carbocyclylalkyl such as cycloalkylalkyl and arylalkyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclylalkyl; heterocyclylalkyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or substituted heterocyclylalkyl; carbocyclyloxy such as cycloalkyloxy and aryloxy, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclyloxy; heterocyclyloxy substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted heterocyclyloxy; carbocyclylalkoxy such as cycloalkylalkoxy and arylalkoxy, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclylalkoxy; heterocyclylalkoxy substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted heterocyclylalkoxy; carbocyclylalkoxycarbonyl such as cycloalkylalkoxycarbonyl and arylalkoxycarbonyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclylalkoxycarbonyl such as cycloalkylalkoxycarbonyl and arylalkoxycarbonyl; heterocyclylalkoxycarbonyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted heterocyclylalkoxycarbonyl; carbocyclylthio such as cycloalkylthio and arylthio, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclylthio such as cycloalkylthio and arylthio; heterocyclyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted heterocyclyl; carbocyclylamino such as cycloalkylamino and arylamino, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclylamino such as cycloalkylamino and arylamino; heterocyclylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted heterocyclylamino; carbocyclylalkylamino such as cycloalkylalkylamino and arylalkylamino, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl or unsubstituted carbocyclylalkylamino such as cycloalkylalkylamino and arylalkylamino; heterocyclylalkylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted heterocyclylalkylamino; carbocyclylsulfamoyl such as cycloalkylsulfamoyl and arylsulfamoyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclylsulfamoyl; heterocyclylsulfamoyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted heterocyclylsulfamoyl;
22 22
carbociclilsulfonilo tal como cicloalquilsulfonilo y arilsulfonilo, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbociclilsulfonilo no sustituido tal como cicloalquilsulfonilo y arilsulfonilo; heterociclilsulfonilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y carbocyclylsulfonyl such as cycloalkylsulfonyl and arylsulfonyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclylsulfonyl such as cycloalkylsulfonyl and arylsulfonyl; heterocyclylsulfonyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and
5 haloalquilo, o heterociclilsulfonilo no sustituido; carbociclilcarbamoílo tal como cicloalquilcarbamoílo y arilcarbamoilo, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbociclilcarbamoílo no sustituido tal como cicloalquilcarbamoílo y arilcarbamoilo; heterociclilcarbamoílo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y Haloalkyl, or unsubstituted heterocyclylsulfonyl; carbocyclylcarbamoyl such as cycloalkylcarbamoyl and arylcarbamoyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclylcarbamoyl such as cycloalkylcarbamoyl and arylcarbamoyl; heterocyclylcarbamoyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and
10 haloalquilo, o heterociclilcarbamoílo no sustituido; carbociclilalquilcarbamoílo tal como cicloalquilalquilcarbamoílo y arilalquilcarbamoílo, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbociclilalquilcarbamoílo no sustituido tal como cicloalquilalquilcarbamoílo y arilalquilcarbamoílo; heterociclilalquilcarbamoílo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, Haloalkyl, or unsubstituted heterocyclylcarbamoyl; carbocyclyl alkylcarbamoyl such as cycloalkylalkylcarbamoyl and arylalkylcarbamoyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclyl alkylcarbamoyl such as cycloalkylalkylcarbamoyl and arylalkylcarbamoyl; heterocyclyl alkylcarbamoyl substituted with one or more substituents selected from the substituent group α, azide,
15 alquilo y haloalquilo, o heterociclilalquilcarbamoílo no sustituido; carbocicliloxicarbonilo tal como cicloalquiloxicarbonilo y ariloxicarbonilo, sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo y haloalquilo, o carbocicliloxicarbonilo no sustituido tal como cicloalquiloxicarbonilo y ariloxicarbonilo; heterocicliloxicarbonilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, azida, alquilo Alkyl and haloalkyl, or unsubstituted heterocyclyl alkylcarbamoyl; carbocyclyloxycarbonyl such as cycloalkyloxycarbonyl and aryloxycarbonyl, substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl, or unsubstituted carbocyclyloxycarbonyl such as cycloalkyloxycarbonyl and aryloxycarbonyl; heterocyclyloxycarbonyl substituted with one or more substituents selected from the substituent group α, azide, alkyl
20 y haloalquilo, o heterocicliloxicarbonilo no sustituido; alquilendioxi sustituido con halógeno, o alquilendioxi no sustituido; oxo; y azida. 20 and haloalkyl, or unsubstituted heterocyclyloxycarbonyl; halogen substituted alkylenedioxy, or unsubstituted alkylenedioxy; oxo; and azide.
El anillo antes mencionado del anillo A y el anillo B cada uno puede estar sustituido con uno o más sustituyentes 25 seleccionados de entre ellos. The aforementioned ring of ring A and ring B each may be substituted with one or more substituents selected from each other.
En la memoria descriptiva, ejemplos del sustituyente de "carbociclo no sustituido", "benceno sustituido o no sustituido", "heterociclo sustituido o no sustituido", "piridina sustituida o no sustituida", "pirimidina sustituida o no sustituida" y "pirazina sustituida o no sustituida" en el anillo A' y el anillo B incluyen halógeno, ciano, hidroxi, nitro, carboxi, alquilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, alquilo no sustituido, In the specification, examples of the substituent of "unsubstituted carbocycle", "substituted or unsubstituted benzene", "substituted or unsubstituted heterocycle", "substituted or unsubstituted pyridine", "substituted or unsubstituted pyrimidine" and "substituted pyrazine or unsubstituted "in ring A 'and ring B include halogen, cyano, hydroxy, nitro, carboxy, alkyl substituted with one or more substituents selected from the substituent group α, unsubstituted alkyl,
30 alcoxi sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, alcoxi no sustituido, amino sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, amino no sustituido, carbamoílo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, carbamoílo no sustituido, alcoxicarbonilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α, y alcoxicarbonilo no sustituido. 30 alkoxy substituted with one or more substituents selected from the substituent group α, unsubstituted alkoxy, amino substituted with one or more substituents selected from the substituent group α, unsubstituted amino, carbamoyl substituted with one or more substituents selected from the substituent group α, carbamoyl substituted, alkoxycarbonyl substituted with one or more substituents selected from the substituent group α, and unsubstituted alkoxycarbonyl.
35 Ejemplos de los sustituyentes que no sean "Z-anillo B" de "carbociclo sustituido o no sustituido" o "heterociclo sustituido o no sustituido" en el anillo A incluyen halógeno, alquilo, alquenilo, alquinilo, alcoxi, alqueniloxi, alquiniloxi Examples of substituents other than "Z-ring B" of "substituted or unsubstituted carbocycle" or "substituted or unsubstituted heterocycle" in ring A include halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy
o ciano. or cyano.
Ejemplos de los sustituyentes de "carbociclo sustituido o no sustituido", "benceno sustituido o no sustituido" o "heterociclo sustituido o no sustituido" en el anillo A' incluyen halógeno. Examples of the substituents of "substituted or unsubstituted carbocycle," "substituted or unsubstituted benzene" or "substituted or unsubstituted heterocycle" on the A 'ring include halogen.
40 Ejemplos de los sustituyentes de "carbociclo sustituido o no sustituido", "heterociclo sustituido o no sustituido", "piridina sustituida o no sustituida", "pirimidina sustituida o no sustituida" o "pirazina sustituida o no sustituida" en el anillo B incluyen halógeno, alquilo, alquenilo, alquinilo, alcoxi, alqueniloxi, alquiniloxi o ciano. Examples of the substituents of "substituted or unsubstituted carbocycle", "substituted or unsubstituted heterocycle", "substituted or unsubstituted pyridine", "substituted or unsubstituted pyrimidine" or "substituted or unsubstituted pyrazine" in ring B include halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy or cyano.
Ejemplos de los sustituyentes de "grupo carbocíclico sustituido o no sustituido", "carbocicliltio sustituido o no sustituido", "carbocicliloxicarbonilo sustituido o no sustituido", "heterociclilo sustituido o no sustituido", "carbocicliloxi 45 sustituido o no sustituido", "carbociclilsulfinilo sustituido o no sustituido", "carbaciclilsulfonilo sustituido o no sustituido", "carbociclo sustituido o no sustituido", "heterociclilo sustituido o no sustituido", "heterocicliloxi sustituido o no sustituido", "heterocicliltio sustituido o no sustituido", "heterocicliloxicarbonilo sustituido o no sustituido", "heterociclilsulfinilo sustituido o no sustituido", "heterociclilsulfonilo sustituido o no sustituido", "heterociclo sustituido Examples of the substituents of "substituted or unsubstituted carbocyclic group", "substituted or unsubstituted carbocyclylthio", "substituted or unsubstituted carbocyclyloxycarbonyl", "substituted or unsubstituted heterocyclyl", "substituted or unsubstituted carbocyclyloxy", "carbocyclylsulfinyl substituted or unsubstituted "," substituted or unsubstituted carbacyclylsulfonyl "," substituted or unsubstituted carbocycle "," substituted or unsubstituted heterocyclyl "," substituted or unsubstituted heterocyclyloxy "," substituted or unsubstituted heterocyclylthioxy " substituted "," substituted or unsubstituted heterocyclylsulfinyl "," substituted or unsubstituted heterocyclylsulfonyl "," substituted heterocycle
o no sustituido", " ciclopentano sustituido o no sustituido", "ciclopenteno sustituido o no sustituido", "ciclohexano or unsubstituted "," substituted or unsubstituted cyclopentane "," substituted or unsubstituted cyclopentene "," cyclohexane
50 sustituido o no sustituido" y "ciclohexeno sustituido o no sustituido" en otro distinto de anillo A., anillo A' y anillo B anteriores incluyen uno o más sustituyentes seleccionados del grupo sustituyente α, alquilo no sustituido y alquilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α. "Substituted or unsubstituted" and "substituted or unsubstituted cyclohexene" in another other than ring A., ring A 'and ring B above include one or more substituents selected from the substituent group α, unsubstituted alkyl and alkyl substituted with one or more substituents selected from the substituent group α.
23 2. 3
[Formula Química 29] [Chemical Formula 29]
25 25
[Formula Química 30] [Chemical Formula 30]
26 26
Estos grupos pueden estar sustituidos con uno o más seleccionados de entre alquilo sustituido con uno o más seleccionados del grupo sustituyente α, alquilo no sustituido y alquilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α en cualquier posición disponible. These groups may be substituted with one or more selected from alkyl substituted with one or more selected from the substituent group α, unsubstituted alkyl and alkyl substituted with one or more substituents selected from the substituent group α at any available position.
Ejemplos de grupos en los que Examples of groups in which
[Formula Química 31] [Chemical Formula 31]
en la que cada símbolo es como se ha definido en el apartado (1), y Q' es carbociclo sustituido o no sustituido, incluyen [Formula Química 32] in which each symbol is as defined in section (1), and Q 'is substituted or unsubstituted carbocycle, include [Chemical Formula 32]
Estos grupos pueden estar sustituidos con uno o más seleccionados de entre alquilo sustituido con uno o más seleccionados del grupo sustituyente α, alquilo no sustituido y alquilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α en cualquier posición disponible. These groups may be substituted with one or more selected from alkyl substituted with one or more selected from the substituent group α, unsubstituted alkyl and alkyl substituted with one or more substituents selected from the substituent group α at any available position.
La frase "Rza y Rzb, junto con el átomo de carbono al que están unidos, pueden formar un carbociclo no aromático 15 sustituido o no sustituido o un heterociclo no aromático sustituido o no sustituido" incluyen los siguientes ejemplos. The phrase "Rza and Rzb, together with the carbon atom to which they are attached, can form a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle" include the following examples.
[Formula Química 33] [Chemical Formula 33]
28 28
Estos grupos pueden estar sustituidos con uno o más seleccionados de entre alquilo sustituido con uno o más seleccionados del grupo sustituyente α, alquilo no sustituido y alquilo sustituido con uno o más sustituyentes seleccionados del grupo sustituyente α en cualquier posición disponible. These groups may be substituted with one or more selected from alkyl substituted with one or more selected from the substituent group α, unsubstituted alkyl and alkyl substituted with one or more substituents selected from the substituent group α at any available position.
5 En la memoria descriptiva, el término "solvato" incluye, por ejemplo, solvatos con disolventes orgánicos e hidratos. Se puede preparar de acuerdo con los métodos conocidos. Ejemplos de solvato incluyen un solvato con acetona, 2butanol, 2-propanol, etanol, acetato de etilo, tetrahidrofurano o dietiléter. Por ejemplo, incluye un hidrato no tóxico y soluble en agua o un solvato tal como un solvato con etanol. En el caso que se forma un hidrato o solvato, el compuesto o la sal pueden coordinarse con cualquier número de moléculas de solvato o moléculas de agua. 5 In the specification, the term "solvate" includes, for example, solvates with organic solvents and hydrates. It can be prepared according to known methods. Examples of solvate include a solvate with acetone, 2butanol, 2-propanol, ethanol, ethyl acetate, tetrahydrofuran or diethyl ether. For example, it includes a non-toxic and water-soluble hydrate or a solvate such as a solvate with ethanol. In the case that a hydrate or solvate is formed, the compound or salt can be coordinated with any number of solvate molecules or water molecules.
10 El compuesto de la fórmula (I) incluye una sal farmacéuticamente aceptable. Ejemplos incluyen sales con metales alcalinos tales como litio, sodio o potasio; metales alcalinotérreos tales como calcio; magnesio; metales de transición tales como zinc o hierro; amonio; bases orgánicas; y aminoácidos; o sales con ácidos inorgánicos tales como ácido clorhídrico, ácido sulfúrico, ácido nítrico, ácido bromhídrico, ácido fosfórico o ácido yodhídrico; y ácidos orgánicos tales como ácido acético, ácido trifluoroacético, ácido cítrico, ácido láctico, ácido tartárico, ácido oxálico, ácido The compound of the formula (I) includes a pharmaceutically acceptable salt. Examples include salts with alkali metals such as lithium, sodium or potassium; alkaline earth metals such as calcium; magnesium; transition metals such as zinc or iron; ammonium; organic bases; and amino acids; or salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid or hydroiodic acid; and organic acids such as acetic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, acid
15 maleico, ácido fumárico, ácido mandélico, ácido glutárico, ácido málico, ácido benzoico, ácido ftálico, ácido bencenosulfónico, ácido p-toluenosulfónico, ácido metanosulfónico o ácido etanosulfónico. Ejemplos específicos son ácido clorhídrico, ácido fosfórico, ácido tartárico y ácido metanosulfónico. Estas sales se pueden formar por métodos ordinarios. Maleic, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid or ethanesulfonic acid. Specific examples are hydrochloric acid, phosphoric acid, tartaric acid and methanesulfonic acid. These salts can be formed by ordinary methods.
Además, el compuesto de la fórmula (I) no está limitado a un isómero específico, sino que incluye todos los posibles In addition, the compound of the formula (I) is not limited to a specific isomer, but includes all possible
20 isómeros, tales como isómeros ceto-enol, isómeros de imina-enamina, diastereoisómeros, isómeros ópticos e isómeros de rotación; y racemato. Por ejemplo, el compuesto de la fórmula (I) en la que R2a es hidrógeno, incluye los siguientes tautómeros. 20 isomers, such as keto-enol isomers, imine-enamine isomers, diastereoisomers, optical isomers and rotation isomers; and racemate. For example, the compound of the formula (I) in which R2a is hydrogen, includes the following tautomers.
[Formula Química 35] [Chemical Formula 35]
30 30
como Pd/C, en presencia o ausencia de una base. Otros métodos adecuados para preparar compuestos tritiados se pueden encontrar en Isotopes in the Physical and Biomedical Sciences, Vol. I, Labeled Compounds (Parte A) Capítulo 6 (1987). Compuestos marcados con 14C se pueden preparar mediante el empleo de materiales de partida que tienen un carbono 14C. as Pd / C, in the presence or absence of a base. Other suitable methods for preparing tritiated compounds can be found in Isotopes in the Physical and Biomedical Sciences, Vol. I, Labeled Compounds (Part A) Chapter 6 (1987). Compounds marked with 14C can be prepared by using starting materials that have a 14C carbon.
5 (Procedimientos Generales) 5 (General Procedures)
Los compuestos de las fórmulas (I) y (Ia) a (If) de la presente invención se pueden preparar por los métodos descritos a continuación. En las etapas siguientes, cuando se posee un sustituyente que interfiere con la reacción, p. ej., hidroxi, mercapto, amino, formilo, carbonilo, carboxi, el sustituyente está protegido por el método tal como los descritos de antemano en Protective Groups in organic Synthesis, y Theodora W Greene (John Wiley & Sons), y el The compounds of formulas (I) and (Ia) to (If) of the present invention can be prepared by the methods described below. In the following steps, when there is a substituent that interferes with the reaction, e.g. For example, hydroxy, mercapto, amino, formyl, carbonyl, carboxy, the substituent is protected by the method as described in advance in Protective Groups in organic Synthesis, and Theodora W Greene (John Wiley & Sons), and the
10 grupo protector se puede separar en una etapa conveniente. 10 protecting group can be separated at a convenient stage.
1) Síntesis del Compuesto (Ia) 1) Synthesis of Compound (Ia)
[Formula Química 38] [Chemical Formula 38]
15 en donde cada símbolo es como se ha definido anteriormente. 15 where each symbol is as defined above.
Etapa 1. Stage 1.
Compuesto b se puede preparar añadiendo un reactivo de titanio tal como triisopropóxido de clorotitanio a enolato, que se obtiene por reacción de un éster objetivo tal como propionato de etilo en presencia de una base tal como diisopropilamida de litio en un disolvente tal como tolueno, diclorometano y tetrahidrofurano, o un disolvente mixto de Compound b can be prepared by adding a titanium reagent such as chlorotitanium triisopropoxide to enolate, which is obtained by reacting an objective ester such as ethyl propionate in the presence of a base such as lithium diisopropylamide in a solvent such as toluene, dichloromethane and tetrahydrofuran, or a mixed solvent of
20 los mismos, añadiendo un compuesto que se puede preparar por los métodos conocidos y haciéndolos reaccionar a -80°C a 30°C, preferiblemente -80°C a 0°C, durante 0,1 a 24 horas, preferiblemente de 0,1 a 12 horas. 20 by adding a compound that can be prepared by known methods and reacting at -80 ° C to 30 ° C, preferably -80 ° C to 0 ° C, for 0.1 to 24 hours, preferably 0, 1 to 12 hours
Etapa 2 Stage 2
Compuesto c se puede preparar añadiendo un reactivo de Grignard tal como bromuro de metilmagnesio que está disponible comercialmente o se pueden preparar por los métodos conocidos o un reductor tal como borano, 25 borohidruro de sodio e hidruro de litio y aluminio en el Compuesto b en un disolvente tal como dioxano, Compound c can be prepared by adding a Grignard reagent such as methylmagnesium bromide that is commercially available or can be prepared by known methods or a reducer such as borane, sodium borohydride and lithium aluminum hydride in Compound b in a solvent such as dioxane,
32 32
- Nº No.
- Estructura RMN (disolvente: orden ascendente del valor de desplazamiento) Structure NMR (solvent: ascending order of offset value)
- imagen77 image77
-
imagen78image78 imagen79image79
- I-16 I-16
-
imagen80image80 imagen81image81
- I-17 I-17
-
imagen82image82 imagen83image83
- I-18 I-18
-
imagen84image84 imagen85image85
- I-19 I-19
-
imagen86image86 imagen87image87
[Tabla 1-4] [Table 1-4]
- Nº No.
- Estructura Nº. Estructura Structure . Structure
- I-20 I-20
-
imagen88 I-28imagen89 image88 I-28image89
81 82 [Tabla 1-5] 81 82 [Table 1-5]
- Nº No.
- Estructura Nº. Estructura Structure . Structure
- imagen90 image90
-
imagen91image91 imagen92image92 imagen93image93
- I-21 I-21
-
imagen94 I-29imagen95 image94 I-29image95
- I-22 I-22
-
imagen96 I-30imagen97 image96 I-30image97
- I-23 I-23
-
imagen98 I-31imagen99 image98 I-31image99
- I-24 I-24
-
imagen100 I-32imagen101 image100 I-32image101
- I-25 I-25
-
imagen102 I-33imagen103 image102 I-33image103
- I-26 I-26
-
imagen104 I-34imagen105 image104 I-34image105
- Nº No.
- Estructura Nº. Estructura Structure . Structure
- imagen106 image106
-
imagen107image107 imagen108image108 imagen109image109
- I-27 I-27
-
imagen110 I-35imagen111 image110 I-35image111
- Nº No.
- Estructura Nº Estructura Structure No. Structure
- I-36 I-36
-
imagen112 I-44imagen113 image112 I-44image113
- I-37 I-37
-
imagen114 I-45imagen115 image114 I-45image115
- I-38 I-38
-
imagen116 I-46imagen117 image116 I-46image117
- I-39 I-39
-
imagen118 I-47imagen119 image118 I-47image119
83 83
Claims (11)
- 11. eleven.
- El compuesto de acuerdo con una cualquiera de las reivindicaciones 6 a 10, en donde -Z-es -C(=O)N(R8)-, su 5 sal farmacéuticamente aceptable o un solvato del mismo. The compound according to any one of claims 6 to 10, wherein -Z-is -C (= O) N (R8) -, its pharmaceutically acceptable salt or a solvate thereof.
- 13. 13.
- El compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 9, 11 y 12, en donde R4a y R4b son 10 ambos hidrógeno, su sal farmacéuticamente aceptable o un solvato del mismo. The compound according to any one of claims 1 to 9, 11 and 12, wherein R4a and R4b are both hydrogen, its pharmaceutically acceptable salt or a solvate thereof.
- 14. 14.
- El compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 3 y 5 a 13, en donde R1 es alquilo C1 a C3 no sustituido, su sal farmacéuticamente aceptable o un solvato del mismo. The compound according to any one of claims 1 to 3 and 5 to 13, wherein R1 is unsubstituted C1 to C3 alkyl, its pharmaceutically acceptable salt or a solvate thereof.
- 15. fifteen.
- El compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 14, en donde R2a y R2b son ambos hidrógeno, su sal farmacéuticamente aceptable o un solvato del mismo. The compound according to any one of claims 1 to 14, wherein R2a and R2b are both hydrogen, its pharmaceutically acceptable salt or a solvate thereof.
- o un heterociclo sustituido o no sustituido, R4a y R4b, junto con el átomo de carbono al que están unidos, pueden formar un carbociclo sustituido o no sustituido or a substituted or unsubstituted heterocycle, R4a and R4b, together with the carbon atom to which they are attached, can form a substituted or unsubstituted carbocycle
- o un heterociclo sustituido o no sustituido, or a substituted or unsubstituted heterocycle,
- o no sustituido, alquiniloxi sustituido o no sustituido, alquiltio sustituido o no sustituido, alqueniltio sustituido o no sustituido, alquiniltio sustituido o no sustituido, acilo sustituido o no sustituido, aciloxi sustituido o no sustituido, ciano, nitro, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo, amino sustituido o no sustituido, carbamoílo sustituido o no sustituido, tiocarbamoílo sustituido o no sustituido, sulfamoílo sustituido o no sustituido, alquilsulfinilo sustituido o no sustituido, alquenilsulfinilo sustituido or unsubstituted, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl substituted, substituted or unsubstituted alkenyloxycarbonyl, alkynyloxycarbonyl, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkylsulfinyl, substituted alkenylsulfinyl
- o no sustituido, alquinilsulfinilo sustituido o no sustituido, alquilsulfonilo sustituido o no sustituido, alquenilsulfonilo sustituido o no sustituido, alquinilsulfonilo sustituido o no sustituido, un grupo carbocíclico sustituido o no sustituido, carbocicliloxi sustituido o no sustituido, carbocicliltiio sustituido o no sustituido, carbociclilalquilo sustituido o no sustituido, carbociclilalcoxi sustituido o no sustituido, carbocicliloxicarbonilo sustituido o no sustituido, carbociclilsulfinilo sustituido o no sustituido, carbociclilsulfonilo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, heterocicliloxi sustituido o no sustituido, heterocicliltio sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, heterociclilalcoxi sustituido o no sustituido, heterocicliloxicarbonilo sustituido o no sustituido, heterociclilsulfinilo sustituido o no sustituido, heterociclilsulfonilo sustituido o no sustituido y R7 es hidrógeno, halógeno, hidroxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alcoxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido, alquiniloxi sustituido or unsubstituted, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, a substituted or unsubstituted carbocyclic group, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclyl, substituted or unsubstituted carbocyclyl or unsubstituted, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclylsulfinyl, substituted or unsubstituted carbocyclylsulfonyl, a substituted or unsubstituted heterocyclyl group, substituted or unsubstituted heterocyclyl or substituted heterocyclyl or unsubstituted, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted heterocyclylsulfinyl, substituted or unsubstituted heterocyclylsulfonyl and R7 is hydrogen, halogen, hi droxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted alkynyloxy
- o no sustituido, acilo sustituido o no sustituido, aciloxi sustituido o no sustituido, ciano, nitro, carboxi, alcoxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, alquilsulfinilo sustituido o no sustituido, alquenilsulfinilo sustituido o no sustituido, alquinilsulfinilo sustituido or unsubstituted, substituted or unsubstituted acyl, substituted or unsubstituted acyloxy, cyano, nitro, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfinyl, substituted or alkenylsulfinyl substituted, substituted alkylsulfinyl
- o no sustituido, alquilsulfonilo sustituido o no sustituido, alquenilsulfonilo sustituido o no sustituido, alquinilsulfonilo sustituido o no sustituido, carbamoílo sustituido o no sustituido, tiocarbamoílo sustituido o no sustituido, sulfamoílo sustituido o no sustituido, amino sustituido o no sustituido, un grupo carbocíclico sustituido o no sustituido, carbocicliloxi sustituido o no sustituido, carbocicliltio sustituido o no sustituido, carbociclilalquilo sustituido o no sustituido, carbociclilalcoxi sustituido o no sustituido, carbocicliloxicarbonilo sustituido o no sustituido, carbociclilsulfinilo sustituido o no sustituido, carbociclilsulfonilo sustituido o no sustituido, un grupo heterocíclico sustituido o no sustituido, heterocicliloxi sustituido o no sustituido, heterocicliltio sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, heterociclilalcoxi sustituido o no sustituido, heterocicliloxicarbonilo sustituido o no sustituido, heterociclilsulfinilo sustituido o no sustituido o heterociclilsulfonilo sustituido o no sustituido, or unsubstituted, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted sulfamoyl, a substituted carbocyclic group or unsubstituted, substituted or unsubstituted carbocyclyloxy, substituted or unsubstituted carbocyclylthio, substituted or unsubstituted carbocyclylalkyl, substituted or unsubstituted carbocyclylalkoxy, substituted or unsubstituted carbocyclyloxycarbonyl, substituted or unsubstituted carbocyclyl, substituted heterocyclic or unsaturated carbocyclic or unsubstituted, substituted or unsubstituted heterocyclyloxy, substituted or unsubstituted heterocyclylthio, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkoxy, substituted or unsubstituted heterocyclyloxycarbonyl, heterocyclylsulfinyl substituted or unsubstituted or substituted or unsubstituted heterocyclylsulfonyl,
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009282184 | 2009-12-11 | ||
JP2009282184 | 2009-12-11 | ||
JP2010237030 | 2010-10-22 | ||
JP2010237030 | 2010-10-22 | ||
PCT/JP2010/072193 WO2011071135A1 (en) | 2009-12-11 | 2010-12-10 | Oxazine derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2590038T3 true ES2590038T3 (en) | 2016-11-17 |
ES2590038T5 ES2590038T5 (en) | 2021-10-19 |
Family
ID=44145678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10836054T Active ES2590038T5 (en) | 2009-12-11 | 2010-12-10 | Oxazine derivative |
Country Status (15)
Country | Link |
---|---|
US (3) | US8999980B2 (en) |
EP (1) | EP2511268B2 (en) |
JP (2) | JPWO2011071135A1 (en) |
KR (1) | KR20120104570A (en) |
CN (1) | CN102834384A (en) |
AU (1) | AU2010328975B2 (en) |
BR (1) | BR112012013854A2 (en) |
CA (1) | CA2783958A1 (en) |
ES (1) | ES2590038T5 (en) |
MX (1) | MX2012006491A (en) |
RU (1) | RU2012129168A (en) |
TW (1) | TWI488852B (en) |
UA (1) | UA110467C2 (en) |
WO (1) | WO2011071135A1 (en) |
ZA (2) | ZA201203777B (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
BRPI0617852A2 (en) | 2005-10-25 | 2011-08-09 | Shionogi & Co | aminodihydrothiazine derivatives as well as compositions containing them |
AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
WO2008133273A1 (en) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Pharmaceutical composition for treatment of alzheimer's disease |
NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
JPWO2010047372A1 (en) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | 2-Aminopyrimidin-4-one and 2-aminopyridine derivatives having BACE1 inhibitory activity |
UY32799A (en) | 2009-07-24 | 2011-02-28 | Novartis Ag | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS |
UA108363C2 (en) | 2009-10-08 | 2015-04-27 | IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS | |
EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
CA2783958A1 (en) | 2009-12-11 | 2011-06-16 | Shionogi & Co., Ltd. | Oxazine derivative |
EP2580200B1 (en) | 2010-06-09 | 2016-09-14 | Janssen Pharmaceutica, N.V. | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
US8927721B2 (en) | 2010-10-29 | 2015-01-06 | Shionogi & Co., Ltd. | Naphthyridine derivative |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
SG191097A1 (en) | 2010-12-22 | 2013-08-30 | Janssen Pharmaceutica Nv | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
US8524897B2 (en) | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
SI2663561T1 (en) | 2011-01-13 | 2016-07-29 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
US8404680B2 (en) * | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
WO2012117027A1 (en) | 2011-03-01 | 2012-09-07 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
CA2825620C (en) | 2011-03-09 | 2019-04-23 | Janssen Pharmaceutica Nv | 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
EP2694521B1 (en) | 2011-04-07 | 2015-11-25 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
EP2703399A4 (en) * | 2011-04-26 | 2014-10-15 | Shionogi & Co | Oxazine derivative and bace 1 inhibitor containing same |
WO2012147762A1 (en) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | Pyridine derivative and bace-1 inhibitor containing same |
US8785436B2 (en) * | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
KR20140041687A (en) | 2011-06-07 | 2014-04-04 | 에프. 호프만-라 로슈 아게 | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors |
US9073909B2 (en) * | 2011-06-07 | 2015-07-07 | Hoffmann-La Roche Inc. | [1,3]oxazines |
JP2014524472A (en) | 2011-08-22 | 2014-09-22 | メルク・シャープ・アンド・ドーム・コーポレーション | 2-Spiro-substituted iminothiazines and their monooxides and dioxides as BACE inhibitors, compositions, and uses thereof |
UY34278A (en) | 2011-08-25 | 2013-04-05 | Novartis Ag | NEW NOXEDINE DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF DISEASES |
US20130073953A1 (en) * | 2011-09-21 | 2013-03-21 | Timothy Onyenobi | News headline screenshot viewing system |
MX357383B (en) * | 2011-12-06 | 2018-07-06 | Janssen Pharmaceutica Nv | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives. |
SG11201403956VA (en) * | 2012-01-26 | 2014-10-30 | Hoffmann La Roche | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
MA37763B1 (en) * | 2012-06-26 | 2017-05-31 | Hoffmann La Roche | Difluoro-hexahydro-cyclopentaoxazinyl and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors |
US9556135B2 (en) | 2012-10-12 | 2017-01-31 | Amgen, Inc. | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
EP2912035A4 (en) * | 2012-10-24 | 2016-06-15 | Shionogi & Co | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
WO2014078314A1 (en) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9489013B2 (en) | 2012-12-20 | 2016-11-08 | Merck Sharp & Dohme Corp. | C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use |
US9309263B2 (en) | 2013-01-29 | 2016-04-12 | Amgen Inc. | Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof |
AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
CN105164121A (en) | 2013-03-08 | 2015-12-16 | 美国安进公司 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
KR102247765B1 (en) | 2013-04-11 | 2021-05-06 | 에프. 호프만-라 로슈 아게 | Bace1 inhibitors |
KR102243133B1 (en) | 2013-06-12 | 2021-04-22 | 얀센 파마슈티카 엔.브이. | 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase(bace) |
KR102243134B1 (en) | 2013-06-12 | 2021-04-22 | 얀센 파마슈티카 엔.브이. | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase(bace) |
JP6387402B2 (en) | 2013-06-12 | 2018-09-05 | ヤンセン ファーマシューティカ エヌ.ベー. | 4-Amino-6-phenyl-5,6-dihydroimidazo [1,5-A] pyrazin-3 (2H) -one derivatives as inhibitors of β-secretase (BACE) |
JO3318B1 (en) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | Bace inhibitors |
WO2015017407A1 (en) | 2013-07-30 | 2015-02-05 | Amgen Inc. | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta- secretase |
WO2015132141A1 (en) * | 2014-03-03 | 2015-09-11 | F. Hoffmann-La Roche Ag | 1,3-oxazine-2-amine derivatives acting as bace inhibitors for the treatment of alzheimer's disease |
TW201623295A (en) * | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | Dihydrothiazine and dihydrooxazine derivatives having BACE1 inhibitory activity |
WO2016012384A1 (en) * | 2014-07-22 | 2016-01-28 | F. Hoffmann-La Roche Ag | Trifluormethyloxazine amidines as bace1 inhibitors |
MX2017001794A (en) | 2014-08-08 | 2017-06-29 | Amgen Inc | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use. |
ES2768823T3 (en) | 2014-12-18 | 2020-06-23 | Janssen Pharmaceutica Nv | 2,3,4,5-Tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrole-5-amine derivatives useful as beta-secretase inhibitors |
US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
MA54101A (en) | 2016-12-15 | 2021-10-27 | Amgen Inc | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE |
AU2017378316B2 (en) | 2016-12-15 | 2021-04-01 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
JP7177773B2 (en) * | 2016-12-15 | 2022-11-24 | アムジエン・インコーポレーテツド | Oxazine derivatives as beta-secretase inhibitors and methods of use |
MA54100A (en) | 2016-12-15 | 2021-10-20 | Amgen Inc | THIAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE |
US11021493B2 (en) | 2016-12-15 | 2021-06-01 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
WO2019208693A1 (en) | 2018-04-27 | 2019-10-31 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity |
JP2022532810A (en) * | 2018-07-06 | 2022-07-20 | 塩野義製薬株式会社 | Condensed heterocyclic derivative with selective BACE1 inhibitory activity |
Family Cites Families (223)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2899426A (en) | 1959-08-11 | Synthesis of l | ||
US3235551A (en) | 1966-02-15 | Novel derivatives of | ||
US3227713A (en) | 1966-01-04 | Azine derivatives | ||
JPH09504278A (en) | 1944-06-01 | 1997-04-28 | ザ、ウェルカム、ファンデーション、リミテッド | Substituted urea and isothiourea derivatives as NO synthase inhibitors |
US3115494A (en) | 1961-10-13 | 1963-12-24 | Mcneilab Inc | 2-amino-5, 6-dihydro-4ii-1, 3-oxazines and a process for their preparation |
BE637923A (en) | 1962-09-29 | |||
US3636116A (en) | 1968-09-03 | 1972-01-18 | Dow Chemical Co | 1 2-substituted indene compounds |
SU465792A3 (en) | 1968-11-06 | 1975-03-30 | Хиноин Гиогисцер-Ес Вегиесцети Термекек Гиара Рт (Фирма) | The method of obtaining heterocyclic compounds |
US3577428A (en) | 1969-04-14 | 1971-05-04 | Colgate Palmolive Co | 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines |
US3719674A (en) | 1971-02-08 | 1973-03-06 | Dow Chemical Co | 1,2-substituted indene compounds |
DE2426653C3 (en) | 1974-06-01 | 1982-05-06 | Bayer Ag, 5090 Leverkusen | Derivatives of 2-amino-1,3-thiazine |
DD140144A1 (en) | 1978-11-08 | 1980-02-13 | Horst Hartmann | PROCESS FOR THE PREPARATION OF P-AMINOPHENYL SUBSTITUTED 2-AMINO-1,3-THIAZINIUM SALTS |
US4311840A (en) | 1980-11-13 | 1982-01-19 | E. R. Squibb & Sons, Inc. | 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones |
JPS62120374A (en) | 1985-11-20 | 1987-06-01 | Yoshitomi Pharmaceut Ind Ltd | 1,3-thiazine or 1,3-oxazine derivative |
JPH0231792Y2 (en) | 1986-01-21 | 1990-08-28 | ||
FI95572C (en) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
CA1332151C (en) | 1988-01-28 | 1994-09-27 | Roman Amrein | Use of a benzamide to treat cognitive disorder |
US5236942A (en) | 1990-04-19 | 1993-08-17 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful in the treatment of Altzheimer's dementia |
US5328915A (en) | 1992-09-17 | 1994-07-12 | E. I. Du Pont De Nemours And Company | Arthropodicidal amidrazone ureas |
SI9300616A (en) | 1992-11-27 | 1994-06-30 | Wellcome Found | Enzyme inhibitors |
GB9418912D0 (en) | 1994-09-20 | 1994-11-09 | Fisons Corp | Pharmaceutically active compounds |
WO1996014842A1 (en) | 1994-11-15 | 1996-05-23 | Merck & Co., Inc. | Substituted heterocycles as inhibitors of nitric oxide synthase |
DE4442116A1 (en) | 1994-11-25 | 1996-05-30 | Cassella Ag | 2-amino-1,3-thiazines as inhibitors of nitric oxide synthase |
WO1996018607A1 (en) | 1994-12-12 | 1996-06-20 | Chugai Seiyaku Kabushiki Kaisha | Aniline derivative having the effect of inhibiting nitrogen monoxide synthase |
JPH08333258A (en) | 1994-12-14 | 1996-12-17 | Japan Tobacco Inc | Thiazine or thiazepine derivative and nitrogen monoxide synthetase inhibitor containing the compound |
DE4444930A1 (en) | 1994-12-16 | 1996-06-27 | Cassella Ag | 2-amino-1,3-thiazepines and their use as inhibitors of nitric oxide synthase |
TW372967B (en) * | 1994-12-27 | 1999-11-01 | Kanebo Ltd | 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof |
EP0843661B1 (en) | 1995-08-11 | 2002-03-27 | Pfizer Inc. | (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate |
JPH0967355A (en) | 1995-08-31 | 1997-03-11 | Tokyo Tanabe Co Ltd | Thiazine derivative, thiazole derivative and their production |
NO307879B1 (en) | 1995-09-18 | 2000-06-13 | Sankyo Co | New urea derivatives with ACAT inhibitory activity and pharmaceuticals containing them |
JPH11513679A (en) | 1995-10-17 | 1999-11-24 | アストラ・フアーマシユウテイカルズ・リミテツド | Drug-active quinazoline compounds |
KR20000005388A (en) | 1996-04-13 | 2000-01-25 | 니콜라스 피터 비가르트 (니크 비가르트), 콜린 레드롭 | Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents |
US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US5952374A (en) | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
SE9703693D0 (en) | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
TW460460B (en) | 1997-11-04 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Heterocyclic compounds having NOS inhibitory activities |
US6294695B1 (en) | 1998-03-26 | 2001-09-25 | Mount Sinai School Of Medicine Of The City University Of New York | Aminobenzoic acid derivatives having anti-tumorigenic activity methods of making and using the same |
AUPP285898A0 (en) | 1998-04-07 | 1998-04-30 | Fujisawa Pharmaceutical Co., Ltd. | Amido derivatives |
SE9802333D0 (en) | 1998-06-29 | 1998-06-29 | Astra Pharma Prod | Novel combination |
US7375125B2 (en) | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
MX226123B (en) | 1999-09-17 | 2005-02-07 | Millennium Pharm Inc | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa. |
US20030060487A1 (en) | 2000-04-12 | 2003-03-27 | Bamdad R. Shoshana | Treatment of neurodegenerative disease |
EP1283039A4 (en) | 2000-05-19 | 2007-05-30 | Takeda Pharmaceutical | -secretase inhibitors |
US6420566B2 (en) | 2000-06-09 | 2002-07-16 | Aventis Pharma S.A. | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof |
US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
AU2002256418A1 (en) | 2001-04-27 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
US6562783B2 (en) | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
BR0214035A (en) | 2001-11-08 | 2005-04-26 | Elan Pharm Inc | Compound |
BR0206368A (en) | 2001-11-09 | 2004-02-10 | Aventis Pharma Sa | Use of 2-amino-4-pyridylmethyl thiazoline derivatives as inductively no synthase inhibitors |
AU2002358874B2 (en) | 2001-11-09 | 2007-09-06 | Aventis Pharma S.A. | 2-amino-4-heteroarylethyl thiazoline derivatives and their use an inhibitors of inducible no-synthase |
RU2004117526A (en) | 2001-11-09 | 2005-04-10 | Авентис Фарма С.А. (Fr) | APPLICATION OF 2-AMINOTIAZOLINE DERIVATIVES AS INHIBITORS OF INDUSTRIAL NO-SYNTHASE |
US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
PL372695A1 (en) | 2002-06-19 | 2005-07-25 | Solvay Pharmaceuticals Gmbh | Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins |
AU2003249983A1 (en) | 2002-07-18 | 2004-02-09 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
WO2004014843A1 (en) | 2002-08-09 | 2004-02-19 | Takeda Chemical Industries, Ltd. | Substituted amino compounds and use thereof |
TW200502221A (en) | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
JP2004149429A (en) | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | Indole compound and application thereof |
JP2006096665A (en) | 2002-10-29 | 2006-04-13 | Ono Pharmaceut Co Ltd | Therapeutic agent for spinal canal stenosis |
WO2004043916A1 (en) | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
RU2252936C2 (en) | 2002-12-05 | 2005-05-27 | Институт физиологически активных веществ РАН | S-substituted [(hetero)aryl]alkylisothioureas, production thereof, pharmaceutical composition, investigation of glutamatergic system, treatment methods (variants) |
MXPA05011503A (en) | 2003-04-25 | 2006-05-31 | Johnson & Johnson | C-fms kinase inhibitors. |
GB0324498D0 (en) | 2003-07-21 | 2003-11-26 | Aventis Pharma Inc | Heterocyclic compounds as P2X7 ion channel blockers |
US7338950B2 (en) | 2003-10-07 | 2008-03-04 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
AU2004299040A1 (en) | 2003-12-15 | 2005-06-30 | Pharmacopeia, Inc. | Heterocyclic aspartyl protease inhibitors |
US20070203147A1 (en) | 2004-03-30 | 2007-08-30 | Coburn Craig A | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors |
EP1747218A2 (en) | 2004-04-30 | 2007-01-31 | Schering Corporation | Neuropeptide receptor modulators |
AU2005264917A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase |
AU2005277283A1 (en) | 2004-08-23 | 2006-03-02 | Merck Sharp & Dohme Corp. | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
EP1791818A1 (en) | 2004-09-14 | 2007-06-06 | The Genetics Company, Inc. | Hydrazone derivatives and their use as beta secretase inhibitors |
WO2006041404A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-compounds and uses thereof |
US20090062282A1 (en) | 2004-10-15 | 2009-03-05 | Astrazeneca Ab | Substituted Amino-Pyrimidones and Uses Thereof |
JP2008523139A (en) | 2004-12-14 | 2008-07-03 | アストラゼネカ・アクチエボラーグ | Substituted aminopyridines and uses thereof |
NZ556546A (en) | 2005-01-07 | 2011-02-25 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
WO2006076284A2 (en) | 2005-01-14 | 2006-07-20 | Wyeth | AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE |
AU2006214627A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | Azolylacylguanidines as beta-secretase inhibitors |
WO2006088705A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | Terphenyl guanidines as [beta symbol] -secretase inhibitors |
WO2006088694A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS |
MX2007011234A (en) | 2005-03-14 | 2007-11-12 | Transtech Pharma Inc | Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors. |
EP1896032B1 (en) | 2005-06-14 | 2012-10-31 | Merck Sharp & Dohme Corp. | The preparation and use of compounds as protease inhibitors |
KR20080025079A (en) | 2005-06-14 | 2008-03-19 | 쉐링 코포레이션 | Aspartyl protease inhibitors |
AU2006259675A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
NZ564222A (en) | 2005-06-14 | 2011-10-28 | Taigen Biotechnology Co Ltd | Pyrimidine compounds |
WO2007002220A2 (en) | 2005-06-21 | 2007-01-04 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as beta-secretase inhibitors |
JP2009500329A (en) | 2005-06-30 | 2009-01-08 | ワイス | Amino-5- (6 membered) heteroarylimidazolone compounds and their use for β-selectase modulation |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
EP1915339A1 (en) * | 2005-08-11 | 2008-04-30 | Boehringer Ingelheim International GmbH | Beta-secretase inhibitors for use in the treatment of alzheimer's disease |
PE20070461A1 (en) | 2005-09-26 | 2007-05-10 | Wyeth Corp | AMINO-5- [4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS B-SECRETASE INHIBITORS |
BRPI0617852A2 (en) | 2005-10-25 | 2011-08-09 | Shionogi & Co | aminodihydrothiazine derivatives as well as compositions containing them |
EP1951682A4 (en) | 2005-11-15 | 2011-06-15 | Astrazeneca Ab | Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use |
TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
EP1951680A4 (en) | 2005-11-15 | 2011-08-10 | Astrazeneca Ab | Novel 2-aminopyrimidinone derivatives and their use |
TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
CN101360716A (en) | 2005-11-21 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer s disease, neurodegeneration and dementia |
JP2009520027A (en) | 2005-12-19 | 2009-05-21 | ワイス | 2-Amino-5-piperidinylimidazolone compounds and their use in the regulation of β-secretase |
AR058381A1 (en) | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 2-AMINOPIRIDIN-4-ONAS AND A PHARMACEUTICAL COMPOSITION |
UY30118A1 (en) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | AMIS TRISUSTITUDE COMPUTER |
WO2007092854A2 (en) | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
WO2007092846A2 (en) | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
JP2009532464A (en) | 2006-04-05 | 2009-09-10 | アストラゼネカ・アクチエボラーグ | 2-Aminopyrimidin-4-one and its use for treating or preventing Aβ-related pathologies |
TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
SI2021335T1 (en) | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Heterocyclic compounds as inhibitors of c-fms kinase |
AU2007258435A1 (en) | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US20080021217A1 (en) | 2006-07-20 | 2008-01-24 | Allen Borchardt | Heterocyclic inhibitors of rho kinase |
TW200817406A (en) | 2006-08-17 | 2008-04-16 | Wyeth Corp | Imidazole amines as inhibitors of β-secretase |
MX2009006227A (en) | 2006-12-12 | 2009-06-22 | Schering Corp | Aspartyl protease inhibitors containing a tricyclic ring system. |
WO2008073365A1 (en) | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors |
TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
WO2008098857A1 (en) | 2007-02-15 | 2008-08-21 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
WO2008133273A1 (en) * | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Pharmaceutical composition for treatment of alzheimer's disease |
AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
JP4846769B2 (en) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
WO2009064418A1 (en) | 2007-11-14 | 2009-05-22 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
US8158620B2 (en) | 2008-01-18 | 2012-04-17 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivatives |
NZ586831A (en) | 2008-01-28 | 2012-02-24 | Janssen Pharmaceutica Nv | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace) |
US7786116B2 (en) | 2008-01-29 | 2010-08-31 | Janssen Pharmaceutica N.V. | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
EP2252595B1 (en) | 2008-02-01 | 2014-03-26 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
BRPI0907563A2 (en) | 2008-02-18 | 2015-08-04 | Hoffmann La Roche | 4,5-Dihydroxazol-2-ylamine derivatives |
PE20091834A1 (en) | 2008-04-22 | 2009-12-19 | Schering Corp | 2-IMINO-3-METHYLPYRROLOOPYRIMIDINONE THIOPHENYL-SUBSTITUTED COMPOUNDS AS BACE-1 INHIBITORS AND COMPOSITIONS CONTAINING THEM |
TWI431004B (en) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace inhibitors |
NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
CA2731209A1 (en) | 2008-07-28 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
WO2010013302A1 (en) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Spiroaminodihydrothiazine derivative |
EP2312945A4 (en) | 2008-08-13 | 2012-05-09 | Merck Sharp & Dohme | Purine derivatives for treatment of alzheimer's disease |
US8685972B2 (en) | 2008-08-13 | 2014-04-01 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives for treatment of alzheimer's disease |
AR073406A1 (en) | 2008-09-30 | 2010-11-03 | Eisai R&D Man Co Ltd | AMINODIHYDROTIAZINES FUSED WITH TETRAHYDROPIRANS, INHIBITORS OF BACE1 AND THE PRODUCTION OF ABETA AMILOID, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES, TALES. |
JPWO2010047372A1 (en) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | 2-Aminopyrimidin-4-one and 2-aminopyridine derivatives having BACE1 inhibitory activity |
US20100125087A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 575 |
US20100125081A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 574 |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
TW201040141A (en) | 2009-03-31 | 2010-11-16 | Shionogi & Co | Isothiourea derivatives or isourea derivatives having BACE1 inhibitory activity |
KR101123178B1 (en) | 2009-04-09 | 2012-06-13 | (주)에스메디 | 2-aryl benzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and phrmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient |
WO2010129864A2 (en) | 2009-05-07 | 2010-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
AR077277A1 (en) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | BICYCLE COMPOUNDS (1,3) TIAZIN-2-AMINA PHARMACEUTICAL FORMULATION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
UY32799A (en) | 2009-07-24 | 2011-02-28 | Novartis Ag | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS |
US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (en) | 2009-10-08 | 2015-04-27 | IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS | |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
EP2500344A4 (en) | 2009-11-13 | 2013-05-01 | Shionogi & Co | Aminothiazine or aminooxazine derivative having amino linker |
EP2509983B1 (en) | 2009-11-16 | 2014-09-17 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
WO2011070781A1 (en) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | Substituted aminothiazine derivative |
JP5554346B2 (en) | 2009-12-09 | 2014-07-23 | 塩野義製薬株式会社 | Pharmaceutical composition for treating or preventing Alzheimer's disease containing a sulfur-containing heterocyclic derivative |
US7964594B1 (en) * | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
CA2783958A1 (en) | 2009-12-11 | 2011-06-16 | Shionogi & Co., Ltd. | Oxazine derivative |
US20120245155A1 (en) | 2009-12-11 | 2012-09-27 | Shionogi & Co., Ltd. | Fused heterocyclic compound having amino group |
UA103272C2 (en) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-amino-5,5-difluoro-5,6-dihydro-4h-[1,3]oxazines as bace1 and/or bace2 inhibitors |
WO2011077726A1 (en) | 2009-12-24 | 2011-06-30 | 塩野義製薬株式会社 | 4-amino-1,3-thiazine or oxazine derivative |
NZ600136A (en) | 2009-12-31 | 2013-09-27 | Novartis Ag | Pyrazine derivatives and their use in the treatment of neurological disorders |
US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
EP2580200B1 (en) | 2010-06-09 | 2016-09-14 | Janssen Pharmaceutica, N.V. | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
JP2013531644A (en) | 2010-06-09 | 2013-08-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 5-Amino-3,6-dihydro-1H-pyrazin-2-one derivatives useful as inhibitors of β-secretase (BACE) |
US20130102618A1 (en) | 2010-06-28 | 2013-04-25 | Janssen Pharmaceutica Nv | 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia |
CA2771928C (en) | 2010-07-13 | 2013-08-06 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
US8815881B2 (en) | 2010-08-09 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
US8609660B2 (en) | 2010-09-22 | 2013-12-17 | Janssen Pharmaceutica Nv | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
US8927721B2 (en) | 2010-10-29 | 2015-01-06 | Shionogi & Co., Ltd. | Naphthyridine derivative |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
SG191097A1 (en) | 2010-12-22 | 2013-08-30 | Janssen Pharmaceutica Nv | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US8524897B2 (en) | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
EA201391029A1 (en) | 2011-01-12 | 2014-01-30 | Новартис Аг | OXAZIN DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF NEUROLOGICAL DISORDERS |
EP2663308A1 (en) | 2011-01-13 | 2013-11-20 | Novartis AG | Bace-2 inhibitors for the treatment of metabolic disorders |
SI2663561T1 (en) | 2011-01-13 | 2016-07-29 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
US9242943B2 (en) | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US8399459B2 (en) | 2011-02-02 | 2013-03-19 | Hoffmann-La Roche Inc. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
US8815841B2 (en) | 2011-02-18 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
WO2012117027A1 (en) | 2011-03-01 | 2012-09-07 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
US9067924B2 (en) | 2011-03-04 | 2015-06-30 | Hoffmann-La Roche Inc. | 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors |
CA2825620C (en) | 2011-03-09 | 2019-04-23 | Janssen Pharmaceutica Nv | 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
US8748418B2 (en) | 2011-03-18 | 2014-06-10 | Hoffmann-La Roche Inc. | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors |
US8877744B2 (en) | 2011-04-04 | 2014-11-04 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
US8754075B2 (en) † | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
EP2703399A4 (en) | 2011-04-26 | 2014-10-15 | Shionogi & Co | Oxazine derivative and bace 1 inhibitor containing same |
WO2012147762A1 (en) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | Pyridine derivative and bace-1 inhibitor containing same |
US8785436B2 (en) † | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
WO2012162334A1 (en) | 2011-05-24 | 2012-11-29 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
JP2012250933A (en) † | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | Pharmaceutical composition containing oxazine derivative for treating or preventing alzheimer's disease |
KR20140041687A (en) † | 2011-06-07 | 2014-04-04 | 에프. 호프만-라 로슈 아게 | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors |
US9073909B2 (en) † | 2011-06-07 | 2015-07-07 | Hoffmann-La Roche Inc. | [1,3]oxazines |
UY34278A (en) † | 2011-08-25 | 2013-04-05 | Novartis Ag | NEW NOXEDINE DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF DISEASES |
US20130073953A1 (en) † | 2011-09-21 | 2013-03-21 | Timothy Onyenobi | News headline screenshot viewing system |
UA111749C2 (en) | 2011-12-05 | 2016-06-10 | Янссен Фармацевтика Нв | 6-difluoromethyl-5,6-dihydro-2H- [1,4] OXASINE-3-AMINE DERIVATIVES |
MX357383B (en) | 2011-12-06 | 2018-07-06 | Janssen Pharmaceutica Nv | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives. |
SG11201403956VA (en) † | 2012-01-26 | 2014-10-30 | Hoffmann La Roche | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
CA2867851A1 (en) † | 2012-03-20 | 2013-09-26 | Elan Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof |
MA37763B1 (en) † | 2012-06-26 | 2017-05-31 | Hoffmann La Roche | Difluoro-hexahydro-cyclopentaoxazinyl and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors |
WO2014010748A1 (en) | 2012-07-10 | 2014-01-16 | Shionogi & Co., Ltd. | Cyclopropane derivative having bace1 inhibiting activity |
JP2014101354A (en) † | 2012-10-24 | 2014-06-05 | Shionogi & Co Ltd | Oxazin derivative having bace1 antagonism |
EP2912035A4 (en) † | 2012-10-24 | 2016-06-15 | Shionogi & Co | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
JP2014101353A (en) † | 2012-10-26 | 2014-06-05 | Shionogi & Co Ltd | Pharmaceutical composition for alzheimer's disease medical treatment or prevention including oxazin derivative |
US9475784B2 (en) | 2012-12-19 | 2016-10-25 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production |
US20150376172A1 (en) † | 2013-01-22 | 2015-12-31 | Thomas Woltering | Fluoro-[1,3]oxazines as bace1 inhibitors |
AU2014223334C1 (en) † | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
CN105164121A (en) † | 2013-03-08 | 2015-12-16 | 美国安进公司 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
JP6155537B2 (en) † | 2013-03-22 | 2017-07-05 | エルジー・ケム・リミテッド | CONDUCTIVE PATTERN LAMINATE, MANUFACTURING METHOD THEREOF, AND ELECTRONIC DEVICE AND TOUCH SCREEN CONTAINING CONDUCTIVE PATTERN LAMINATE |
KR102247765B1 (en) † | 2013-04-11 | 2021-05-06 | 에프. 호프만-라 로슈 아게 | Bace1 inhibitors |
WO2015132141A1 (en) † | 2014-03-03 | 2015-09-11 | F. Hoffmann-La Roche Ag | 1,3-oxazine-2-amine derivatives acting as bace inhibitors for the treatment of alzheimer's disease |
TW201623295A (en) † | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | Dihydrothiazine and dihydrooxazine derivatives having BACE1 inhibitory activity |
WO2016001266A1 (en) † | 2014-07-04 | 2016-01-07 | F. Hoffmann-La Roche Ag | Fluoro-[1,3]oxazines as bace1 inhibitors |
WO2016012384A1 (en) † | 2014-07-22 | 2016-01-28 | F. Hoffmann-La Roche Ag | Trifluormethyloxazine amidines as bace1 inhibitors |
WO2017061534A1 (en) † | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
JP2017071603A (en) † | 2015-10-09 | 2017-04-13 | 塩野義製薬株式会社 | Pharmaceutical composition comprising dihydrothiazine or dihydrooxazine derivative |
JP7177773B2 (en) † | 2016-12-15 | 2022-11-24 | アムジエン・インコーポレーテツド | Oxazine derivatives as beta-secretase inhibitors and methods of use |
MA54101A (en) † | 2016-12-15 | 2021-10-27 | Amgen Inc | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE |
-
2010
- 2010-12-10 CA CA2783958A patent/CA2783958A1/en not_active Abandoned
- 2010-12-10 WO PCT/JP2010/072193 patent/WO2011071135A1/en active Application Filing
- 2010-12-10 AU AU2010328975A patent/AU2010328975B2/en not_active Ceased
- 2010-12-10 TW TW099143216A patent/TWI488852B/en not_active IP Right Cessation
- 2010-12-10 JP JP2011545253A patent/JPWO2011071135A1/en not_active Withdrawn
- 2010-12-10 KR KR1020127014809A patent/KR20120104570A/en not_active Application Discontinuation
- 2010-12-10 UA UAA201208561A patent/UA110467C2/en unknown
- 2010-12-10 BR BR112012013854A patent/BR112012013854A2/en not_active IP Right Cessation
- 2010-12-10 ES ES10836054T patent/ES2590038T5/en active Active
- 2010-12-10 RU RU2012129168/04A patent/RU2012129168A/en not_active Application Discontinuation
- 2010-12-10 EP EP10836054.6A patent/EP2511268B2/en active Active
- 2010-12-10 CN CN2010800648635A patent/CN102834384A/en active Pending
- 2010-12-10 US US13/513,839 patent/US8999980B2/en not_active Expired - Fee Related
- 2010-12-10 MX MX2012006491A patent/MX2012006491A/en active IP Right Grant
-
2012
- 2012-05-23 ZA ZA2012/03777A patent/ZA201203777B/en unknown
-
2013
- 2013-05-17 ZA ZA2013/03603A patent/ZA201303603B/en unknown
-
2015
- 2015-02-20 US US14/627,700 patent/US9290466B2/en not_active Expired - Fee Related
- 2015-09-03 JP JP2015173564A patent/JP2016028057A/en not_active Ceased
-
2016
- 2016-02-11 US US15/041,683 patent/US9656974B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8999980B2 (en) | 2015-04-07 |
EP2511268B1 (en) | 2016-07-13 |
EP2511268A4 (en) | 2013-04-17 |
TWI488852B (en) | 2015-06-21 |
JPWO2011071135A1 (en) | 2013-04-22 |
AU2010328975A1 (en) | 2012-06-14 |
ZA201203777B (en) | 2013-08-28 |
MX2012006491A (en) | 2012-07-03 |
US9290466B2 (en) | 2016-03-22 |
JP2016028057A (en) | 2016-02-25 |
UA110467C2 (en) | 2016-01-12 |
US20160159757A1 (en) | 2016-06-09 |
US20120245157A1 (en) | 2012-09-27 |
ZA201303603B (en) | 2015-02-25 |
US9656974B2 (en) | 2017-05-23 |
AU2010328975B2 (en) | 2015-01-22 |
US20150166491A1 (en) | 2015-06-18 |
CA2783958A1 (en) | 2011-06-16 |
EP2511268A1 (en) | 2012-10-17 |
ES2590038T5 (en) | 2021-10-19 |
WO2011071135A1 (en) | 2011-06-16 |
EP2511268B2 (en) | 2021-02-17 |
CN102834384A (en) | 2012-12-19 |
KR20120104570A (en) | 2012-09-21 |
BR112012013854A2 (en) | 2019-09-24 |
TW201127833A (en) | 2011-08-16 |
RU2012129168A (en) | 2014-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2590038T3 (en) | Oxazine derivative | |
US20120245155A1 (en) | Fused heterocyclic compound having amino group | |
ES2476027T3 (en) | Aminodihydrotriazine derivatives | |
US8883779B2 (en) | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them | |
US20120245154A1 (en) | Substituted aminothiazine derivative | |
US20120238557A1 (en) | Aminothiazine or aminooxazine derivative having amino linker | |
AR068950A1 (en) | BICYCLE HETEROCICLE DERIVATIVES AND METHODS OF USE OF THE SAME | |
WO2012147762A1 (en) | Pyridine derivative and bace-1 inhibitor containing same | |
JP2010521528A (en) | Indolizine and its aza-like derivatives as CNS active compounds | |
US20130217705A1 (en) | Naphthyridine derivative | |
RU2012149633A (en) | ORGANIC COMPOUNDS | |
ES2584684T3 (en) | Betulin propenoate derivatives | |
ME01564B (en) | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors | |
CN109790135A (en) | For treating or preventing compound, composition and the method for symptom relevant to gout or hyperuricemia | |
TW200804257A (en) | Inhibitors of histone deacetylase for the treatment of disease | |
ES2362683T3 (en) | METHANOSULFONATE OF 4 - [(3-FLUOROPHENOXY) PHENYLMETILE] PIPERIDINE: USES, SYNTHESIS PROCEDURES AND PHARMACEUTICAL COMPOSITIONS. | |
TW200413313A (en) | 2,4-substituted indoles | |
ES2566755T3 (en) | FXa inhibitors with cyclic amidoxime or cyclic amidrazone as a P4 subunit, procedures for their preparations, and pharmaceutical compositions and derivatives thereof | |
EP3564242B1 (en) | Compound for selectively inhibiting kinase and use thereof | |
CN107530349A (en) | As A2Alkynylamino formic acid esters/trans carbamate of the xanthine substitution of B antagonists | |
FR2876692A1 (en) | 2-AMIDO-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | |
WO2008051637A2 (en) | Pyridazinone compounds | |
JP2020023570A (en) | 2,6-di-substituted pyridine derivative | |
TW201011042A (en) | [1,2,4]thiadiazine 1,1-dioxide compounds | |
TW200920362A (en) | Alkylsulfone derivatives |